RECOMBINANT HVT VECTORS EXPRESSING AVIAN PATHOGEN ANTIGENS AND USES THEREOF

专利摘要:
recombinant hvt vectors expressing avian pathogen antigens and their uses. the present invention provides recombinant turkey herpesvirus (hvt) vectors containing and expressing antigens from avian pathogens, compositions comprising the recombinant hvt vectors, polyvalent vaccines comprising the recombinant hvt vectors and one or more wild-type viruses or recombinant vectors. the present invention further provides methods of vaccination against a variety of avian pathogens and a method of producing the recombinant hvt vectors
公开号:BR112014013276B1
申请号:R112014013276-3
申请日:2012-11-29
公开日:2021-07-27
发明作者:Michel Bublot；Teshome Mebatsion；Joyce Pritchard；Perry Linz
申请人:Merial, Inc.；
IPC主号:

专利说明:

CROSS REFERENCE FOR RELATED ORDERS
[0001] This application claims priority to US Provisional Patent Application US 61/564,877 filed November 30, 2011 and US Provisional Patent Application US 61/694,957 filed August 30, 2012. FIELD OF THE INVENTION
[0002] The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use as safe vehicles of vaccination to protect against a variety of pathogens. It also refers to a multivalent composition or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of preparing and using recombinant viral vectors. BACKGROUND OF THE INVENTION
[0003] Bird vaccination is widely used to protect flocks of birds against devastating diseases, including Newcastle disease (ND), Gumboro disease (IBD), Marek's disease (MD), infectious bronchitis (IB), laryngotracheitis infectious (ILT) and avian influenza (AI). ND is caused by avian paramyxovirus 1 (APMV-1), also called ND virus (NDV) which belongs to the Paramyxoviridae family. MD is caused by herpesvirus Gallid 2 (family Herpesviridae) also called MD virus serotype 1 (MDV1). IB is caused by the IB virus (IBV) belonging to the Coronaviridae family, ILT is caused by a Gallid 1 herpesvirus (Herpesviridae family) also called ILT virus (ILTV) and AI is caused by the AI virus (AIV) belonging to the Orthomyxoviridae family .
[0004] A series of recombinant avian viral vectors have been proposed with the aim of vaccinating birds against these avian pathogens. The viral vectors used comprise avipox viruses, especially for poultry (EP - A - 0.517,292), Marek's virus such as serotypes 2 and 3 (HVT) (WO-A-87/04463), or, alternatively, the ITLV, NDV and avian adenoviruses. When some of these recombinant avian viral vectors were used for vaccination, they exhibit varying levels of protection.
[0005] Various recombinant turkey herpesviruses (HVT, also called Meleagrid herpesvirus 1 or MDV serotype 3) vectors expressing antigens from various pathogens (US Patent Nos. 5,980,906, 5,853,733, 6, 183,753, 5,187,087), including IBDV, NDV , VLT and AIV have been developed and licensed. Of particular interest is a VP2 protective gene expressing HVT vector which has clear advantages over classical IBD vaccines (Bublot et al. J.Comp Path.2007, Vol.137, S81-S84; US 5,980,906). Other HVT vectors of interest are those expressing either NDV (Morgan et al 1992, dis Avian 36, 858-70; US 6,866,852; US 5,650,153) or VLT protective gene(s) ( Johnson et al, 2010 Avian Dis 54, 1251 -1259; US 6,299,882; US 5,853,733). One of the practical problems of using several HVT-based recombinant vaccines together is their interference. Inferior protection is induced against at least one of the diseases when two recombinant HVTs expressing different antigens are mixed (Rudolf Heine 2011; Issues of the Poultry Recombinant Viral Vector Vaccines which May Cause an Effect on the Economic Benefits of those Vaccines; Veterinary Poultry Association (WVPA) Congress in Cancun, Mexico, August 14-18, 2011; Slacum G, Hein R. and Lynch P., 2009, The compatibility of recombinant HVTs with other Marek's disease vaccines, 58th Western Poultry Disease Conference, Sacramento , CA, USA, March 23rd-25th, p 84)).
[0006] The combination of HVT and SB-1, a Gallid herpesvirus 3 vaccine strain (MDV serotype 2 or MDV-2) demonstrated a synergistic effect on MD protection (Witter and Lee, 1984, Avian Pathology 13, 75-92 ). To solve the interference problem, which is of interest to evaluate the HVT virus as a vaccine vector to express one or more protective antigen(s) against a variety of avian pathogens.
[0007] The SB-1 genome has been cloned and characterized by bacterial artificial chromosome (BAC) (Petherbridge, et al., J. Virol. Methods 158, 11-17, 2009; Singh et al., Research in Veterinary Science 89 , 140-145, 2010). The MDV2 SB-1 sequence was recently obtained and analyzed (Spatz and Schat, Virus Gene 42, 331-338, 2011). A virus SB-1 glycoprotein E deletion was described by Petherbridge, et al. (J. Virol. Methods 158, January 1-17, 2009). However, no research has been reported using SB-1 as a viral vector expressing foreign protective genes.
[0008] Considering the potential effect of animal pathogens such as NDV and IBDV on veterinary public health and the economy, efficient methods of preventing infection and protecting animals are needed. There is a need for a solution of combined effective vector vaccines and an appropriate method for producing the vaccine, which can alleviate the problem of interference observed between two HVT-based vector vaccines. SUMMARY OF THE INVENTION
[0009] The present invention showed surprising result when polyvalent compositions or vaccines that comprise a single or dual HVT vector were effective to protect animals against a variety of avian pathogens without interference. Surprising results were also observed when various combinations of promoters, codon optimized gene, poly-A tails and insertion sites conferred different levels of efficiency and stability for the expression of one or more heterologous genes in vivo.
[0010] The present invention relates to a recombinant HVT vector comprising one or more heterologous polynucleotides encoding and expressing at least one antigen of an avian pathogen.
[0011] The present invention provides a composition or a vaccine comprising one or more recombinant HVT vectors comprising one or more heterologous polynucleotides encoding and expressing at least one antigen of an avian pathogen.
[0012] The present invention provides a polyvalent composition or vaccine comprising one or more recombinant HVT vectors comprising heterologous polynucleotides encoding and expressing at least one antigen of an avian pathogen, and one or more SB1 recombinant vectors comprising heterologous polynucleotides that codes for and expresses at least one antigen of an avian pathogen.
[0013] The present invention relates to a method of vaccinating an animal, or inducing an immunogenic or protective response in an animal, comprising at least a single administration of the composition or vector of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] The following detailed description, given by way of example, and which is not intended to limit the invention to the specific embodiments described, may be understood in conjunction with the accompanying figures, incorporated herein by reference, in which:
[0015] Figure 1 is a table showing the SEQ ID NO assigned to each DNA and protein sequence.
[0016] Figure 2 illustrates the structure of the HVT genome and its insertion sites.
[0017] Figure 3 shows the plasmid map of pHM103.
[0018] Figure 4 shows the results of PCR analysis of vHVTl 14.
[0019] Figure 5 shows the results of the dual immunofluorescence assay.
[0020] Figure 6 shows the Southern blot results of vHVTl14.
[0021] Figure 7 represents the analysis of immunoprecipitation and Western blot results for vHVTl 14.
[0022] Figure 8 represents Western blot analysis of immunoprecipitated sample from vHVT306 infected cells.
[0023] Figure 9 represents Western blot analysis of immunoprecipitated samples from infected cells VSB 1-009.
[0024] Figure 10 represents the result of the challenge study of vHVT304 and vHVTl14 against NDV ZJ1 and CA02.
[0025] Figure 11 shows the result of viral shedding after NDV CA02 and ZJ1 challenge.
[0026] Figure 12 shows the viral shedding result after NDV Chimalhuacan challenge.
[0027] Figure 13 shows sequence alignment and identity percentages.
[0028] Figure 14 shows the DNA and protein sequences. DETAILED DESCRIPTION OF THE INVENTION
[0029] It should be noted that in this disclosure and particularly in the claims, terms such as "comprises", "understood", "comprising" and the like may have the meaning ascribed to it in US patent law; for example, they can mean "include", "include", "including", and the like; and that terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in US Patent law, for example, they allow for elements not explicitly recited, but exclude elements that are found in the state. of the technique or that affect a basis or new feature of the invention.
[0030] Unless otherwise stated, the technical terms in accordance with conventional usage. Definitions of common terms in molecular biology can be found in Benjamin Lewin, Genes V. published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (Eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: the Global Reference Desk, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
[0031] The singular terms "a," "an," and "o" include references to the plural, unless the context clearly indicates otherwise. Likewise, the word "or" is intended to include "and" unless the context clearly indicates otherwise. The word "or" any member of a special list and also includes any combination of the members of that list.
[0032] The term "animal" is used herein to include all mammals, birds and fish. The animal as used herein may be selected from the group consisting of equine (e.g. horses), canine (e.g. dogs, foxes, wolves, jackals, coyote), feline (e.g. lions, tigers, cats domestic, wild cats, other large cats and other felines including leopards and lynx), cattle (eg cattle), pigs (eg pigs), sheep (eg sheep, goats, llamas, bison), birds ( eg chicken, duck, goose, turkey, quail, pheasant, parrot, finches, falcon, crow, ostrich, rhea and cassowary), primate (eg prosimian, tarsier, monkey, gibbon, monkey), humans and fish . The term "animal" also includes an individual animal at all stages of development, including embryonic and fetal stages.
The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of consecutive amino acid residues.
[0034] The term "nucleic acid", "nucleotide" and "polynucleotide" are used interchangeably and refer to RNA, DNA, cDNA, or RNAc and its derivatives, such as those containing modified backbones. It should be appreciated that the invention provides polynucleotides comprising sequences complementary to those described herein. The "polynucleotide" contemplated in the present invention includes both the forward (5' to 3') and the complementary reverse strand (3' to 5'). Polynucleotides according to the invention can be prepared in different ways (for example, by chemical synthesis, by gene cloning, etc.) and can take different forms (for example, linear or branched, single or double stranded, or its hybrid, primers, probes, etc).
[0035] The term "genomic DNA" or "genome" are used interchangeably and refer to the hereditary genetic information of a host organism. Genomic DNA comprises DNA from the nucleus (also referred to as chromosomal DNA), but also DNA from plastids (eg, chloroplasts) and other cell organelles (eg, mitochondria). The genomic DNA or genome contemplated in the present invention also refers to the RNA of a virus. The RNA can be either a plus strand or a minus strand RNA. The term "genomic DNA" contemplated in the present invention includes genomic DNA that contains sequences complementary to those described herein. The term "genomic DNA" also refers to messenger RNA (mRNA), complementary DNA (cDNA), and complementary RNA (cRNA).
[0036] The term "gene" is used widely to refer to any polynucleotide segment associated with a biological function. Thus, genes or polynucleotides include introns and exons as in genomic sequence, or just coding sequences, as in cDNA, such as an open reading frame (ORF), starting from the initiation codon (methionine codon) and ending with a termination sign (final codon). Genes and polynucleotides can also include regions that regulate their expression, such as transcription initiation, translation, and transcription termination. Thus, promoters and ribosome binding regions are also included (in general, these regulatory elements are found approximately between 60 and 250 nucleotides upstream of the start codon of the coding sequence or the gene; Doree SM et al; Pandher K et al. ; Chung JY et al), transcription terminators (in general, the terminator is located within approximately 50 nucleotides downstream of the coding sequence termination codon or the CK gene; Ward et al). Gene or polynucleotide also refers to a nucleic acid fragment that expresses functional mRNA or RNA, or encodes a specific protein, and that includes regulatory sequences.
The term "heterologous DNA" as used herein refers to DNA derived from a different organism, such as a cell type or species other than that of the recipient. The term also refers to a DNA or fragment of the same genome as the host's DNA, in which the heterologous DNA is inserted into a region of the genome that is different from its original location.
As used herein, the term "antigen" or "immunogenic" means a substance that induces a specific immune response in a host animal. The antigen can comprise a set of organism, dead, attenuated or alive; a subunit or part of an organism; a recombinant vector containing an insert with immunogenic properties; a part or fragment of DNA capable of inducing an immune response against the presentation of a host animal; a polypeptide, an epitope, a hapten, or any combination thereof. Alternatively, the immunogen or antigen may comprise a toxin or antitoxin.
[0039] The term "immunogenic protein or peptide" as used herein includes polypeptides that are immunologically active in the sense that, once administered to the host, it is capable of evoking a humoral and/or cell-like immune response directed against the protein. Preferably, the protein fragment is such that it has substantially the same immunological activity as the total protein. Thus, a protein fragment according to the invention comprises, or consists essentially of, or consists of at least one epitope or antigenic determinant. An "immunogenic" protein or polypeptide, as used herein, includes the full-length protein sequence, its analogs, or its immunogenic fragments. By "immunogenic fragment" is meant a fragment of a protein that includes one or more epitopes and thus elicits the immune response described above. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. For example, linear epitopes can be determined by, for example, concurrently synthesizing a large number of peptides on solid supports, peptides corresponding to portions of the protein molecule, and which react with antibodies against the peptides, while the peptides are still bound to the supports . Likewise, conformational epitopes are easily identified by determining the spatial conformation of amino acids, such as, for example, x-ray crystallography and two-dimensional nuclear magnetic resonance.
[0040] The term "immunogenic protein or peptide" further encompasses deletions, additions and substitutions to the sequence, since the polypeptide functions to produce an immune response as defined herein. The term "conservative variation" means the replacement of an amino acid residue with another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence such that the encoded amino acid residue does not change another biologically similar residue. In this regard, particularly preferred substitutions will generally be conservative in nature, that is, those substitutions that occur within a family of amino acids. For example, amino acids are generally divided into four families: (1) acid-aspartate and glutamate; (2) basic; lysine, arginine, histidine; (3) non-polar - alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar-glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan and tyrosine are sometimes classified as aromatic amino acids. Examples of conservative variations include replacing a methionine residue with another hydrophobic residue, or replacing a polar residue with another polar residue, such as replacing arginine with lysine, glutamic acid with aspartic acid, or glutamine with asparagine, and similar; or a similar conservative substitution of an amino acid for a structurally related amino acid, which will not have a major effect on biological activity. Proteins having substantially the same amino acid sequence as the reference molecule, but which have small amino acid substitutions that do not substantially affect the immunogenicity of the protein are therefore within the definition of the reference polypeptide. All polypeptides produced by these modifications are included herein. The term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid, provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
[0041] The term "epitope" refers to the location on an antigen or hapten to which specific B cells and/or T cells respond. The term is also used interchangeably with "antigenic determinant" or "site antigenic determinant". Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.
An "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to the composition or vaccine of interest. Generally, an "immune response" includes, but is not limited to, one or more of the following effects: the production of antibodies, B cells, T helper cells, and/or cytotoxic T cells, specifically directed to an included antigen or antigens. in the composition or vaccine of interest. Preferably, the host will exhibit a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. This protection will be demonstrated by either a reduction or lack of symptoms normally exhibited by an infected host, a faster recovery time and/or a reduced viral titer in the infected host.
[0043] The term "recombinant" and "genetically modified" are used interchangeably and refer to any modification, alteration or engineering of a polynucleotide or protein in its native or structural form, or any modification, alteration or engineering of a polynucleotide or the protein in its native or surrounding environment. Modification, alteration or engineering of a polynucleotide or protein may include, but is not limited to, deletion of one or more nucleotides or amino acids, deletion of an entire gene, codon optimization of a gene, conservative amino acid substitution, insertion of one or more heterologous polynucleotides.
The term "dual HVT construct" or "dual HVT vector" refers to an HVT viral vector comprising two heterologous polynucleotides.
The terms "vaccine or polyvalent composition", "vaccine or combination or combo composition" and "vaccine or multivalent composition" are used interchangeably to refer to a composition or vaccine containing more than one composition or vaccine. The vaccine or polyvalent composition can contain two, three, four or more compositions or vaccines. The vaccine or polyvalent composition may comprise recombinant viral vectors, active or attenuated or killed wild-type viruses, or a mixture of recombinant viral vectors and wild-type viruses, in active or attenuated or killed forms.
[0046] One embodiment of the invention provides a recombinant HVT viral vector comprising one or more heterologous polynucleotides encoding and expressing at least one polypeptide antigen or from an avian pathogen. The HVT strains used for the recombinant viral vector can be any HVT strain, including, but not limited to, the HVT FC126 strain (Igarashi T. et al, J. Gen. Virol. 70, 1789-1804, 1989).
[0047] Another embodiment of the invention provides a recombinant viral vector SB-1 comprising one or more heterologous polynucleotides encoding and expressing at least one polypeptide antigen or an avian pathogen. The SB-1 strains can be any SB-1 strains, including, but not limited to, Commercial Marek's Disease Vaccine (SB-1 vaccine) (Merial Select Inc., Gainesville, GA 30503, USA), the SB strain -1 having the genome sequence as defined by GenBank accession number HQ840738.1.
The genes coding for antigens or polypeptide may be those coding for Newcastle Disease virus fusion protein (NDV-F), Newcastle Disease virus hemagglutinin neuraminidase (NDV-HN), glycoprotein C from Marek's Disease Virus (gC), Marek's Disease Virus (gB) Glycoprotein B, Marek's Disease Virus (gE) Glycoprotein I, Marek's Disease Virus (gl) Glycoprotein H. Marek's Disease Virus (gH), Marek's Disease Virus G glycoprotein (gG), Marek's Disease Virus L glycoprotein (gL), Gumboro's Disease Virus (IBDV) VP2, IBDV VPX, IBDV VP3, VP4 IBDV, ILTV glycoprotein B, ILTV glycoprotein I, ILTV UL32, ILTV glycoprotein D, ILTV glycoprotein E, ILTV glycoprotein C, influenza hemagglutinin (HA), influenza neuraminidase (NA), protective genes derived from Mycoplasma gallisepticum (MG ), or Mycoplasma synoviae (MS), or combinations thereof. The antigen or polypeptide may be any antigen from avian pathogens selected from the group consisting of encephalomyelitis influenza virus, avian reovirus, avian paramyxovirus, avian metapneumovirus, avian influenza virus, bird adenovirus, avian smallpox virus, coronavirus influenza, avian rotavirus, chick anemia virus, avian astrovirus, avian parvovirus, coccidiosis (Eimeria sp.), Campylobacter sp., Salmonella sp., Pasteurella sp., Avibacterium sp., Mycoplasma gallisepticum, Mycoplasma synoviae, Clostridium sp., and E. coli.
[0049] Furthermore, homologues of the aforementioned antigen or polynucleotides are understood to be within the scope of the present invention. As used herein, the term "homologous" includes orthologs, analogs and paralogs. The term "analog" refers to two polynucleotides or polypeptides that have the same or similar function, but that have evolved separately in foreign organisms. The term "orthologs" refers to two polynucleotides or polypeptides from different species but which evolved from a common ancestral gene by speciation. Orthologs usually encode polypeptides having the same or similar functions. The term "paralogs" refers to two polynucleotides or polypeptides that are related by duplication within a genome. Paralogs often have different functions, but these functions can be related. Analogs, orthologs, and paralogs of a wild-type polypeptide can differ from the wild-type polypeptide through post-translational modifications, amino acid sequence differences, or both. In particular, homologues of the invention generally exhibit at least 80 - 85%, 85 - 90%, 90 - 95%, or 95%, 96%, 97%, 98%), 99%) identity. sequence, with all or part of the above described polynucleotide or polypeptide sequences of antigens, and will have a similar function.
[0050] In one embodiment, the present invention provides a recombinant HVT or SB-1 viral vector comprising one or more heterologous polynucleotides encoding and expressing the NDV-F antigen or polypeptide. In one aspect of the embodiment, the NDV-F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) identity. sequence to a polypeptide having the sequence as defined in SEQ ID NO: 2, 4, 6, 33, 35, or 37, or a conservative variant thereof, an allelic variant, which is a homologue or an immunogenic fragment comprising at least eight, or at least ten consecutive amino acids from one of these polypeptides, or a combination of these polypeptides. In another aspect of the embodiment, the heterologous polynucleotide encodes an NDV-F antigen or polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99 % sequence identity with a polypeptide having the sequence as defined in SEQ ID NO: 2, 4, 6, 33, 35, or 37. In yet another aspect of the embodiment, the heterologous polynucleotide is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity of a polynucleotide having the sequence as defined in SEQ ID NO: 1, 3, 5 , 32, 34, or 36.
[0051] Variants include allelic variants. The term "allelic variant" refers to a polynucleotide or a polypeptide containing polymorphisms that lead to changes in the amino acid sequences of a protein and that exist within a natural population (eg, a virus species or variety). Such natural allelic variations can typically result in 1 - 5% variance of a polynucleotide or a polypeptide. Allelic variants can be identified by sequencing the nucleic acid sequence of interest in several different species, which can be easily accomplished by using hybridization probes to identify the same genetic locus of the gene in such species. Any and all nucleic acid and amino acid variations resulting from polymorphisms or variations which are the result of natural allelic variation and which do not alter the functional activity of the gene of interest are intended to be within the scope of the invention.
[0052] The term "identity" with respect to sequences may refer, for example, to the number of positions with identical nucleotides or amino acids, divided by the number of nucleotides or amino acids in the shorter of the two sequences, where the alignment of the two sequences can be determined, according to the algorithm of Wilbur and Lipman (Wilbur and Lipman). Sequence identity or sequence similarity between two amino acid sequences, or sequence identity between two nucleotide sequences can be determined using the NTI Vector software package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA). When the RNA sequences are said to be similar to, or have a degree of sequence identity or homology to the DNA sequences, the thymidine (T) in the DNA sequence is considered equal to the uracil (U) in the RNA sequence . Thus, RNA sequences are within the scope of the invention, and can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in the RNA sequences.
[0053] The polynucleotides of the disclosure include sequences that are degenerate as a result of the genetic code, for example, the use of codons optimized for a specific host. As used herein, "optimized" refers to a polynucleotide that is genetically modified to increase its expression in a given species. To provide optimized polynucleotides encoding NDV-F polypeptides, the DNA sequence of the NDV-F protein gene can be modified to 1) comprise codons preferred by highly expressed genes of a particular species; 2) comprise a content of A + T or G + C in the nucleotide base composition substantially found in said species; 3) form an initiation sequence for said species; or 4) eliminate sequences that cause RNA destabilization, improper polyadenylation, degradation and extinction, or those that form secondary structure staples or RNA splicing sites. The increased expression of the NDV F protein in said species can be achieved by using the frequency of use of distribution codons in eukaryotes and prokaryotes, or in a particular species. The term "Preferred codon usage frequency" refers to the preference exhibited by a specific host cell in using nucleotide codons to specify a given amino acid. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the description, while the amino acid sequence of the NDV-F polypeptide encoded by the nucleotide sequence is functionally unaltered.
[0054] Successful expression of the heterologous polynucleotides by the infective recombinant/modified virus requires two conditions. First, heterologous polynucleotides must be inserted, or inserted into a region of the virus genome, so that the modified virus remains viable. The second condition for the expression of inserted heterologous polynucleotides is the presence of regulatory sequences that allow the expression of the gene in the viral base (for example: promoters, enhancers, splicing and intron donor and acceptor sites, Kozak translation consensus sequence of initiation, polyadenylation signals, untranslated sequence elements).
The insertion site may be any non-essential region of the HVT genome, including, but not limited to, the region comprised between the ATG of the UL55 ORF and the UL junction, with the adjacent repeat region (US 5,980,906) , the IG1 locus, the IG2 locus, the IG3 locus, the UL43 locus, the US10 locus, the SORF3/US2 locus (see Fig. 2.)
[0056] In general, it is advantageous to use a strong promoter functional from eukaryotic cells. Promoters include, but are not limited to, an immediate early cytomegalovirus (CMV), guinea pig CMV promoter, an SV40 promoter, pseudorabies virus promoters such as the glycoprotein X promoter, Herpes Simplex Virus-1 such as such as alpha 4 promoter, Marek's disease virus promoters (including MDV-1, MDV-2 and HVT) such as those directing the expression of glycoproteins gC, gB, GE, gl, laryngotracheitis infectious virus promoters such as such as those of the glycoprotein gB, gE, gl, gD genes, or other herpesvirus promoters.
[0057] One embodiment of the invention provides a recombinant HVT vector comprising a heterologous polynucleotide encoding and expressing the NDV-F antigen or polypeptide. In one aspect of the embodiment, the polynucleotide encoding the NDV-F polypeptide is operably linked to the SV40 promoter with the sequence as defined in SEQ ID NO: 9 and therefore expression of the NDV-F antigen or polypeptide is regulated by the SV40 promoter. In another aspect of the embodiment, the expression of the NDV-F antigen or polypeptide is regulated by the SV40 polyA signal with the sequence as defined in SEQ ID NO: 11. In yet another aspect of the embodiment, the polynucleotide encoding the NDV -F or polypeptide is operably linked to the MDV gB promoter having the sequence as defined in SEQ ID NO: 38 and therefore the expression of the NDV-F antigen or polypeptide is regulated by the MDV gB promoter.
[0058] Another embodiment of the invention provides a double recombinant HVT vector comprising a first heterologous polynucleotide encoding and expressing the NDV-F antigen or polypeptide and a second polynucleotide encoding and expressing the IBDV VP2 antigen or polypeptide. In one aspect of the embodiment, the NDV-F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with a polypeptide having the sequence as defined in SEQ ID NO: 2, 4, 6, 33, 35, or 37. In another aspect of the embodiment, the IBDV VP2 antigen or polypeptide is at least 70%, 75%, 80 %, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with a polypeptide having the sequence as defined in SEQ ID NO: 8 or 42. In another aspect, the polynucleotide encoding the NDV-F polypeptide is operably linked to the SV40 promoter with the sequence as defined in SEQ ID NO:9 and the expression of NDV-F antigen or polypeptide is regulated by the SV40 promoter. In yet another aspect, the expression of NDV-F antigen or polypeptide is regulated by the SV40 polyA signal having the sequence as defined in SEQ ID NO:11 or the synthetic polyA signal having the sequence as defined in SEQ ID NO: 12. In another aspect, the expression of IBDV VP2 antigen or polypeptide is regulated by the CMV-IE promoter having the sequence as defined in SEQ ID NO: 10 and the SV40 polyA signal with the sequence such as defined in SEQ ID NO: ll.
[0059] Yet another embodiment, the invention provides a recombinant dual HVT vector comprising two polynucleotides encoding and expressing the IBDV VP2 antigens or polypeptides. In one aspect of the embodiment, the IBDV VP2 antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with a polypeptide having the sequence as defined in SEQ ID NO: 8 or 42. In one aspect, the polynucleotide encoding a first IBDV VP2 antigen or polypeptide is operably linked to the CMV-IE promoter having the sequence as defined in SEQ ID NO:10, and the polynucleotide encoding a second IBDV VP2 antigen or polypeptide is operably linked to the guinea pig CMV promoter having the sequence as defined in SEQ ID NO:43. In another aspect, the expression of a first IBDV VP2 antigen or polypeptide is regulated by the CMV-IE promoter having the sequence as defined in SEQ ID NO:10 and the SV40 polyA signal with the sequence as defined in SEQ ID NO:11, and a expression of a second IBDV VP2 antigen or polypeptide is regulated by the promoter of Guinea pig CMV having the sequence as defined in SEQ ID NO:43 and the synthetic polyA signal having the sequence as defined in SEQ ID NO:12. IBDV VP2 or polypeptide can be inserted into one or more regions of the locus selected from the group consisting of IG1, IG2, US10, SORF3-US2 and gD of the HVT genome. In one embodiment, the present invention relates to a pharmaceutical composition or vaccine comprising one or more HVT or SB-1 recombinant viral vectors of the present invention and a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant.
[0060] In another embodiment, the present invention provides a composition or a vaccine comprising an HVT viral vector that comprises a polynucleotide encoding an NDV-F antigen, an SV40 promoter and, optionally, a carrier, excipient, vehicle or a pharmaceutically or veterinarily acceptable adjuvant. In another embodiment, the present invention provides a pharmaceutical composition or vaccine comprising a first HVT vector comprising a polynucleotide encoding an NDV-F antigen, a second HVT vector comprising a polynucleotide encoding an IBDV VP2 antigen, and optionally , a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. In another embodiment, the present invention provides a pharmaceutical or vaccine composition comprising an HVT vector comprising a polynucleotide encoding an NDV-F antigen, an SB-1 vector comprising a polynucleotide encoding an NDV-F antigen optionally a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. The pharmaceutical composition or vaccine of the present invention may comprise a first HVT vector comprising a polynucleotide encoding an NDV-F antigen, a second HVT vector comprising a polynucleotide encoding an IBDV VP2 antigen, an SB-1 vector comprising a polynucleotide encoding an NDV F antigen, optionally, a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant.
[0061] In yet another embodiment, the present invention provides a composition or a vaccine comprising a dual HVT viral vector comprising: i) a first heterologous polynucleotide encoding and expressing an NDV-F antigen or polypeptide; ii) a second polynucleotide that encodes and expresses an IBDV VP2 antigen or polypeptide; and iii) optionally, a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. In another embodiment, the present invention provides a composition or a vaccine comprising a dual HVT viral vector comprising two polynucleotides encoding and expressing the IBDV VP2 antigens or polypeptides, and optionally a carrier, excipient, vehicle or adjuvant pharmaceutically or veterinarily acceptable. In yet another embodiment, the composition comprising the dual HVT viral vector further comprises an HVT vector comprising a polynucleotide encoding an IBDV VP2 antigen or an SB-1 vector comprising a polynucleotide encoding an NDV-F antigen , or a combination thereof. Pharmaceutically or veterinarily acceptable carriers, adjuvants, vehicles or excipients are well known to those skilled in the art. For example, a pharmaceutically or veterinarily acceptable carrier or adjuvant or vehicle, or excipient or diluent can be a Marek's disease vaccine diluent used for MD vaccines. Other carrier, or an adjuvant or a vehicle, or pharmaceutically or veterinarily acceptable excipients that can be used for the methods of the present invention include, but are not limited to, 0.9% NaCl solution (e.g., saline) or a phosphate buffer, poly(L-glutamate) or polyvinylpyrrolidone. The carrier, or a pharmaceutically or veterinarily acceptable vehicle or excipients may be any compound or combination of compounds that facilitates administration of the vector (or protein expressed from a vector of the invention, in vitro), or to facilitate transfection or infection and / or improve the conservation of the vector (or protein). Dose volumes and doses are discussed in the general description herein and can also be determined by one of skill in the art from this disclosure, in combination with knowledge of the prior art, without any undue experimentation.
Optionally, other compounds may be added as pharmaceutically or veterinarily acceptable carriers or adjuvants or vehicles or excipients, including, but not limited to, alum; CpG oligonucleotides (ODN), in particular, the ODN 2006, 2007, 2059, or 2135 (Pontarollo RA et al, Vet Immunol Immunopath, 2002, 84:43 - 59; Wernette CM et al, Vet Immunol Immunopath, 2002, 84: 223-236; Mutwiri G. et al, Vet Immunol Immunopath, 2003, 91:89-103 ); poly-PolyU, dimethyldioctadecylammonium bromide (DDA) ("Vaccine Subunit Design and Adjuvant Approach", edited by Michael F. Powell and Mark J. Newman, Pharmaceutical Biotechnology, 6: P.03, p.157); N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)propanediamine (such as avridine®) {Ibid, p. 148); carbomer, chitosan (see, for example, U.S. Patent No. 5,980,912).
[0063] Pharmaceutical compositions and vaccines according to the invention may comprise or consist essentially of one or more adjuvants. Adjuvants suitable for use in the practice of the present invention are: (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl-derived polymers, (2) immunostimulant (ISS) sequences, such as oligodeoxyribonucleotide sequences with one or more unmethylated CpG units (Klinman et al, 1996; WO98/16247), (3) an oil-in-water emulsion, such as the SPT emulsion described on p 147 of "Vaccine Design, Subunit and Adjuvant Approach", published by M Powell, M. Newman, Pleem an Press 1995, and the MF59 emulsion described on p 183 of the same paper, (4) the cationic lipids containing a quaternary ammonium salt, eg, DDA (5) cytokines, (6) of aluminum hydroxide or aluminum phosphate, (7) saponin or (8) other adjuvants discussed in any document cited and incorporated by reference to immediate application, or (9) any combinations or mixtures.
[0064] Another aspect of the invention relates to a method for inducing an immune response in an animal against one or more antigens or a protective response in an animal against one or more avian pathogens, wherein the method comprises inoculating the animal, at least once with the pharmaceutical composition or vaccine of the present invention. Yet another aspect of the invention relates to a method for inducing an immune response in an animal to one or more antigens or a protective response in an animal against one or more avian pathogens in a prime-boost administration regimen, which it comprises at least one primary administration and at least one booster administration with at least one common polypeptide, antigen, epitope or immunogen. The immunological composition or vaccine used in the primary administration may be the same, it may be different in nature from those used as a booster.
[0065] Avian pathogens can be Newcastle Disease Virus (NDV), Gumboro Disease Virus (ie IBDV or Gumboro Disease Virus), Marek's Disease Virus (MDV), Infectious Laryngotracheitis Virus ( VLT), avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian metapneumovirus, avian influenza virus, avian adenovirus, avian smallpox virus, avian coronavirus, avian rotavirus, avian parvovirus, avian virus and avian anemia virus, coccidiosis sp.), Campylobacter sp., Salmonella sp., Mycoplasma gallisepticum, Mycoplasma synoviae, Pasteurella sp., Avibacterium sp., E. coli or Clostridium sp.
[0066] Generally, an administration of the vaccine is performed either at one day of age, subcutaneously or intramuscularly or in ovo in the 17 - 19 day old embryo. A second administration can be done within the first 10 days of age. Animals are preferably at least 17 days old or one day old at the time of first administration.
[0067] A variety of routes of administration in day-old chicks can be used, such as subcutaneously or intramuscularly, intradermally, transdermally. In ovo vaccination can be performed in the amniotic sac and/or the fetus. Commercially available in ovo and SC administration devices can be used for vaccination.
[0068] The invention will now be further described by means of the following non-limiting examples. EXAMPLES
[0069] The construction of recombinant DNA inserts, plasmids and viral vectors was performed using the standard molecular biology techniques described by J. Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). Example 1 Construction of recombinant vHVT114 expressing NDV-F Preparation of donor plasmid pHM103 + Fopt
Plasmid pHM103 (Merial Ltd.) containing the Intergenic I arms of HVT FC126 (see Fig. 2), SV40 promoter and SV40 poly A were digested with NotI, dephosphorylated, and the 5.6kb fragment was gel extracted . A 1.7 kb NotI flanked fragment of a chemically synthesized codon optimized genotype V11d NDV-F gene (SEQ ID NO:1, coding for SEQ ID NO:2) was also digested with NotI and the 1, 7 kb was gel extracted. The 5.6 and 1.7 kb fragments were ligated to create pHM103 + Fopt (Fig. 3). Recombinant HVT viral vector generation
[0071] An in vitro recombination (IVR) was performed by co-electroporation of secondary chicken embryo fibroblast cells (2nd CEF cells) using pHM103 + Fopt as the donor plasmid and viral DNA isolated from the HVT FC126 strain . Co-electroporation was performed with 1 x 107 2° CEF in 300 ul of Opti-MEM and shocked at 150 volts with 950 capacitance in a 2 mm electroporation cuvette. Transfected cells were seeded in 96-well plate and incubated for 5 days. Cells grown in 96-well plates were then repeated in two 96-well plates. One set of 96-well plates was used for IFA using polyclonal chicken sera against NDV-F to identify positive wells containing recombinants and another set of 96-well plates was used to recover infected cells from the positive wells.
Recombinant viral purification was performed for the first time by 96-well plate duplication and IFA selection for the wells containing the most IFA positive plates with the least amount of IFA negative plates. Wells matching these criteria were then harvested and adjusted to 1 ml DMEM + 2% FBS. From the 1 ml stock, 5 - 20 µl were removed and mixed with 1 X 107 CEFs in 10 ml DMEM + 2% FBS and aliquoted to a new 96 well plate having individual HVT plates per well. The supernatant from the wells containing the individual plates were tested for the absence of parental virus by PCR. After five rounds of plaque purification, a recombinant virus designated as vHVT114 was isolated and purity was tested by IFA and PCR to confirm the expression of NDV-F and the absence of parental virus. PCR Analysis of Recombinant vHVT114
[0073] DNA was extracted from vHVT114 by phenol/chloroform extraction, ethanol precipitated, and resuspended in 20 mM HEPES. The PCR primers (shown in Table 1) were specifically designed to identify the presence of codon optimized NDV-F, the SV40 promoter, as well as the purity of the recombinant virus from FC126 CL2 parental virus. PCR was performed using 200 ng of template DNA together with the primer pairs indicated in Table 1 and the conditions of the PCR cycles are as follows: 94°C for 2 minutes; 30 cycles of 94°C for 30 sec, at 55°C for 30 sec, 68°C for 3 minutes; 68°C for 5 minutes. The expected PCR products are shown in Table 2. The PCR results are shown in Figure 4. As shown in Figure 4, the sizes of the PCR products after gel electrophoresis match well with the expected sizes and band patterns. Table 1
Table 2

Immunofluorescence testing was performed using vHVT114 which was passaged more than ten times in addition to an experimental pre-master seed (pre-MSV). The pre-MSV and pre-MSV 12 materials were diluted 1:100 on average. Fifty microliters of the diluted virus was added to 10 ml of DMEM + 2% FBS with 1 X 107 CEFs and then aliquoted into a 96-well plate (100 µl/well). Plates were incubated for 3 days at 37°C, 5% CO 2 until viral plaques were visible. Plates were fixed with 95% ice-cold acetone for three minutes and washed three times with PBS. Chicken antisera against Newcastle Disease Virus (lot # C0139, Charles Rivers Laboratory) at 1:1000 were added along with monoclonal antibody G-78 (Merial Limited) at 1:3000 and the plates were incubated at 37°C for 1 hour. After the 1 hour incubation the plates were washed three times with PBS and FITC anti-chicken (lot # F8888, Sigma) was added along with Alexz Fluor 568 anti-mouse (IgG) donkey (lot # A 10037, Molecular Probe) to 1:500. Again, plates were incubated at 37°C for 1 hour. After the 1 hour incubation, cells were washed three times with PBS. A small amount of PBS was added to prevent the monolayer from drying and auto-fluorescing. The cells were then visualized with a fluorescent microscope using either a tetramethylrhodamine isothiocyanate (TRITC) or a fluorescein isothiocyanate (FITC) filter in combination.
Viral plaques vHVT114 were visualized using both FITC and TRITC filters for double staining. FITC test showed NDV-F expression and TRITC test showed HVT expression. Because of the small wells of the 96-well plates, each well was recorded with the plates counted with the TRITC filter first and then counted with the FITC filter. More than 500 plaques were counted for the pre-MSV and pre-MSV 12 passage. All plaques were positive for both FITC and TRITC on both plates. (FIG. 5) Southern blot of recombinant vHVT114
[0076] Total genomic DNA was extracted from HVT FC126 and vHVT114, according to the standard genomic DNA extraction protocol. For each restriction digest, 3 ug of genomic DNA (1 ng of donor plasmid) was used with a total digestion volume of 20 l for each sample. Genomic DNA from HVT FC126 (negative control), pHM103 + Fopt plasmid donor, and vHVT114 were digested overnight at 37°C with BamHI, PstI, Sphl, and Ncol restriction endonucleases. Restriction fragments of HVT FC126 (negative control), pHM103 + Fopt plasmid donor, and genomic DNA vHVT114 were separated by a 1% agarose gel and transferred to a positively charged nylon membrane. Following hybridization and North2South Chemiluminescent Detection Kit (Thermo Scientific) to the manufacturers instructions, the membrane was prehybridized for 1 hour and then hybridized with a biotinylated NDV-F probe overnight at 55°C. hybridization overnight, several stringency washes were performed until the membrane was placed in a blocking buffer, with the addition of Streptavidin-HRP. After washing the membrane of any uncoupled Streptavidin-HRP the luminal and peroxide substrate solution was added. The membrane was then exposed to X-ray film and developed. Zones where the DNA-bound biotinylated probe was chemiluminescent and were captured on the membrane by X-ray. Table 3 shows the expected Southern blot bands using the NDV-F probe. Southern blot results revealed digestion patterns as expected (Fig. 6). Table 3 NDV-F probe
Sequence analysis of the inserted region in recombinant vHVT114
[0077] Analysis of vHVTl14 genomic DNA region was performed by PCR amplification. A total of 10 primers were used to amplify the entire cassette as well as for the BamHI-I flanking arms used in the donor plasmid. The 4.727 kb PCR product was gel purified and the entire fragment was sequenced using the sequencing primers. The result confirmed that the vHVT114 sequence contains the correct SV40 promoter, NDV-F optimized codons and SV40 polyA sequences, which exactly match the sequence described for donor plasmid pHM103 + Fopt in SEQ ID NO: 18. Western blot analysis of recombinant vHVT114
Approximately 2 x 106 chicken fibroblast cells were infected at ~0.1 MOI with vHVT114 Pre-MSV. After two days of incubation at 37°C, infected as well as uninfected cells were harvested using a cell scraper, after removing the medium and washing with PBS. Cells were harvested with 1 ml PBS and centrifuged. Cell pellets were lysed following the classic IP Pierce Kit (lot # 26146, Thermo Scientific). 100 µl of anti-NDV-F 001C3 monoclonal antibody (Merial Ltd.) was used to form the immune system complex. The antibody/lysate sample was added to Protein A/G Plus agarose to capture the immune complex. The immune complex was washed three times to remove unbound material and then eluted in the 50 µl volume using sample elution buffer under non-reducing conditions. After boiling for 5 minutes, 10 l of the samples were loaded onto a 10% acrylamide gel (Invitrogen). The PAGE gel was run in MOPS buffer (Invitrogen) at 200volts for 1 hour. Then, the gel was transferred to a PVDF membrane.
The Western Blot Detector System Kit TMB protein (KPL, cat # 54 - 11-50), was used to dry the PVDF membrane using the reagents and following the manufacturer's instructions. After blocking the membrane for 1 hour at room temperature, the membrane was then washed three times in wash buffer IX, five minutes each and then soaked in blocking buffer containing 1:1000 dilution of chicken serum raised against NDV virus ( Lot #139 CO, Charles River Laboratories). After washing three times in a wash buffer, the membrane was incubated with a goat anti-chicken IgG peroxidase (KPL, cat # 14-24-06) at a 1:2000 dilution for 1 hour at room temperature. The membrane was then washed three times in wash buffer IX, five minutes each. 5 ml of TMB membrane peroxidase substrate was added to the membrane and gently shaken for about 1 minute. The development reaction was stopped by placing the membrane in water.
The immunoprecipitation technique and Western blot detected a protein of approximately 55 kD in the vHVT1 14 sample that corresponds to the expected size of the F1 component of the NDV-F protein (FIG. 7). Example 2: Construction of recombinant vHVTHO, vHVTIII, vHVT112, VHVT113 and vHVT116 expressing NDV-F.
[0081] Generation and characterization of recombinant HVT vHVT 110, vHVT 111, vHVTl 12, vHVTl 13, and vHVTl 16 was done essentially the same way as for vHVTl 14 described in example 1. Table 4 shows the unique characteristics for each construct in around the expression cassettes, including their sequences. Table 4. Characteristics of individual recombinant HVT expression cassettes

Plasmid pCD046 (material owned by Merial) containing the Intergenic I arms of HVT FC126, CMV promoter mouse and SV40 poly A was digested with NotI, dephosphorylated, and a 6.6kb fragment was gel extracted. A 1.7 kb NotI flanked fragment of a chemically synthesized NDV-F gene containing the wild-type F sequence (SEQ ID NO: 3, which codes for SEQ ID NO: 4) was also digested with NotI and the 1 fragment. .7 kb was gel extracted. The 6.6 kb and 1.7 kb fragments were ligated to create a donor plasmid pCD046 + NDV-F wt (SEQ ID NO: 21 for vHVT110) used in transfection to generate recombinant vHVT110 by insertion region sequencing confirmed that vHVT110 contains the correct mCMV promoter sequence, the wild type of the NDV-F gene and the SV40 polyA. The sequence also exactly matches the sequence described for plasmid donor pCD046 + NDV-F by weight in SEQ ID NO:21. vHVIII
Plasmid pHM103 (material owned by Merial), containing the Intergenic Arm I of HVTFC126, the promoter of SV40 and SV40 polyA was digested with NotI, dephosphorylated, and the 5.6 kb fragment was gel extracted. A 1.7 kb NotI flanked fragment of a chemically synthesized NDV-F gene containing the wild type sequence F (SEQ ID NO: 3, which codes for SEQ ID NO: 4) was also digested with NotI and a 1 fragment. .7 kb was gel extracted. The 5.6 kb and 1.7 kb fragments were ligated to create a donor plasmid (SEQ ID NO:22 for vHVT1110). Used in transfection to generate recombinant vHVT111. Insertion region sequencing confirmed that vHVT111 contains the correct sequences of the SV40 promoter, the wild type of the NDV-F gene and the SV40 polyA, as shown in donor plasmid sequence pHM103 + NDV-F wt (SEQ ID NO :22). vHVT12
A fragment encompassing the wild-type NDV-F YZCQ synthetic gene (SEQ ID NO:34 encoding SEQ ID NO:35) was excised from plasmid pUC57 NDV-F YZCQ (synthesized by GeneScript) using NotI and inserted into the same site as plasmid pCD046 which contains the mCMV promoter and SV40 tail polyA. Bound material was transformed using Top 10 Oneshot kit (Cat # C404002, Invitrogen). Bacterial colonies were grown in LBamp broth, plasmid extracted using Qiagens MiniSpin Prep kit, and screened for insertion orientation. The correct donor plasmid was designated pCD046 + NDV-F VII YZCQ. Large-scale cultures were developed and plasmid extraction was performed using Qiagens Maxi Prep kit. Transient expression of the maxi preps was verified using Fugene Transfection Reagent in Chicken Embryo Fibroblast Cells (CEF's) and polyclonal chicken sera against NDV.
Plasmid pCD046 + NDV-F VII YZCQ (SEQ ID NO: 29). It was used in transfection to generate recombinant vHVT112. Insertion region sequencing confirmed that vHVT112 contains the correct mCMV promoter sequences, the wild type NDV-Gene F YZCQ and the SV40 polyA. The sequence also exactly matches the sequence described for donor plasmid pCD046 + NDV-F VII YZCQ in SEQ ID NO: 29. vHVT113
[0086] A fragment encompassing the synthetic NDV Texas F gene (SEQ ID NO:36 encoding SEQ ID NO:37) was excised from plasmid pUC57 NDV Texas F (synthesized by GeneScript) using NotI and inserted into the same site of plasmid pCD046 which contains mCMV promoter and SV40 polyA tail. Bound material was transformed using Top 10 Oneshot kit (Cat # C404002, Invitrogen). Bacterial colonies were grown in LBamp broth, plasmid extracted using Qiagens MiniSpin Prep kit, and screened for insertion orientation. The correct donor plasmid was designated pCD046 + Texas NDV-F. Large-scale cultures were developed and plasmid extraction was performed using Qiagens Maxi Prep kit. Transient expression of the maxi preps was verified using Fugene Transfection Reagent in Chicken Embryo Fibroblast Cells (CEF's) and polyclonal chicken sera against NDV.
The plasmid pCD046 Texas + NDV-F (SEQ ID NO: 30) was used in the transfection to generate recombinant vHVT113. Insertion region sequencing confirmed that vHVT113 contains the correct mCMV promoter sequences, the wild type NDV. F Texas gene F and the SV40 polyA. The sequence also exactly matches the sequence described for plasmid donor pCD046 Texas + NDV-F in SEQ ID NO:30. vHVT039
[0088] The MDV gB promoter (SEQ ID NO: 38) was amplified from DNA extracted from MDV1 strain RB1B by PCR using primer HM101 (5' -CCG-GAA-TTC-AGC-TGT-ATT-ACG-TCG- ATA-GAC-3') (SEQ ID NO: 44) and HM102 (51 -ATA-AGA-GCG-GCC-CGC-GTG-AGA-TCT-TGA-TAA-TGA-TG-3') (SEQ ID NO : 45). The former contains an EcoRI site and the latter contains a NotI site for ligating the EcoRI/NotI digested 630 bp PCR product into the EcoRI/NotI digested plasmid pCD046. The ligation product was used to transform competent DH5α cells. Colonies were picked and tested for the presence of the inserted PCR fragment by restriction analysis with EcoRI and NotI. The resulting plasmid was designated pHM102.
[0089] The velogenic strain NDV Texas (genotype IV) was cultivated at 11 days of age, embryonated eggs SPF and semi-purified. Total RNA was extracted and an RT PCR was performed using two F-ATG primers (5'TAT-AGC-GGC-CGC-AAG-ATG-GGC-CCT-AGA-TCT-TCT-ACC-AG 3') (SEQ ID NO: 46) and F-STOP (5'CGA-GCG-GGC-CGC-TAT-TCA-TTT-TGT-AGT-GGC-TCT-C 3') (SEQ ID NO: 47). They allow full amplification of the NDV F gene with addition of NotI site upstream of ATG and downstream stop codons. The 1.7 kb PCR fragment was digested with NotI and ligated into NotI-digested pHM102. The resulting plasmid was designated pHM119 and was used as a donor plasmid in the in vitro recombination study by co-transfecting CEF cells with HVT parental DNA to generate vHVT039 as described above. Insertion region sequencing confirmed that vHVT039 contains the correct MDV gB promoter sequences, the unmodified wild type of the NDV-F gene from the Texas strain (SEQ ID NO:32 encoding SEQ ID NO:33) and the SV40 polyA, as shown in the partial sequence of donor plasmid pHM119 (SEQ ID NO:31). vHVT116
Plasmid pHM103 (material owned by Merial), containing the Intergenic Arm I of HVT FC126, the promoter of SV40 and SV40 polyA was digested with NotI, dephosphorylated, and the 5.6kb fragment was gel extracted. A NotI flanked by a 1.7 kb fragment, genotype CA02 gene V NDV-F optimized from the chemically synthesized codon (SEQ ID NO: 5, which codes for SEQ ID NO: 6) was also digested with NotI and the fragment of 1.7 kb was gel extracted. The 5.6 and 1.7 kb fragments were ligated to create pHM103 + NDV-F CA02 (SEQ ID NO: 23 for vHVT161) used in transfection to generate recombinant vHVT161. Insertion region sequencing confirmed that vHVT116 contains the correct SV40 promoter sequences of NDV-F gene CA02 with optimized codons and SV40 polyA, as shown in donor plasmid sequence pHM103 + NDV-F wt (SEQ ID NO: 23 ). Discussion
[0091] Several cassettes under the mCMV or non-CMV promoter were inserted into different loci of the HVT genome (Table 4). Despite repeated attempts, the generation of a construct with a combination of mCMV and the codon-optimized F sequence was not successful beyond passage 2. However, when the wild-type sequence was driven by a stable mCMV promoter construct, vHVT1 10 could be generated. Furthermore, recombinant vHVT111 with the wild-type F sequence under the SV40 promoter was also stable for more than 10 passages in vitro. Surprisingly, an optimized F codon sequence under the SV40 promoter was also found to be stable for more than 10 passages in vitro (eg, vHVT114 and vHVT116). These results indicate the delicate balance between promoter strength and gene nature that controls the generation of a genetically stable (or non-codon optimized) HVT construct. Example 3 Construction of vHVT306, a double HVT vector expressing NDV-F and IBDV VP2
The pHVT donor plasmid US2 SV-Fopt-synPA was constructed containing the SV40 promoter, the synthetic NDV F codons optimized VII gene synthetic polyA tail flanked by SORF3 and sequences from US2 arm of HVT FC126. Generation of Recombinant Viruses
[0093] A standard homologous recombination process was followed by co-electroporation of secondary CEF cells using donor plasmid pHVT US2 SV-Fopt-synPA and viral DNA isolated from vHVT13 (an HVT vector expressing the IBDV VP2 gene, Merial Limited) . Essentially, the procedure described in example 1 for vHVT114 was followed to generate, purify and characterize recombinant plaques by immunofluorescence.
[0094] After five rounds of plaque purification, pure recombinant virus (vHVT306) was isolated and the purity of vHVT306 was tested and confirmed by IFA and PCR. PCR analysis
[0095] Viral DNA was extracted from vHVT306 pre-master virus seed (pre-MSV) stock by QIA DNeasy Blood & Tissue Kit (Qiagen cat #69506). The PCR primers were designed to identify the presence of the optimized NDV F, the wild type NDV F, the SV40 promoter, the mCMV promoter, the flanking arms of the US2 of the HVT virus and the SB-1 of the virus.
[0096] PCR amplification with different primers confirmed that vHVT306 has the expected amplification patterns and amplicons. Expression Analysis
[0097] Indirect immunofluorescent assay (IFA) was performed on pre-MSV vHVT306 stock. CEFs that were inoculated with vHVT306 were fixed with ice cold 95% acetone for three minutes at room temperature and for 10 min, air dried. After three washes with PBS, two primary antibodies, chicken anti-Newcastle Disease virus serum (Charles Rivers Laboratories cat # 10100641, lot # C0117A) at 1:500 dilution and monoclonal antibody L78 against HVT (Merial Select, Gainesville, GA) a 1:3000 dilution was added and incubated for 45 min at 37°C. After three washes with PBS, two secondary, goat anti-chicken IgG antibodies ~ fluorescein (KPL cat # .02-24-06, lot # 10020 l) at 1:500 dilution and donkey anti-mouse IgG-Alexa Fluor 568 (Molecular Probe # A10037, lot # 989784) at 1:300 dilution were added. Plates were incubated at 37°C for 45 min and followed by three washes with PBS. Cells were observed to identify IFA positive plaques with a fluorescent microscope using fluorescein isothiocyanate (FITC)- and tetramethylrhodamine isothiocyanate (TRITC)-filters from Nikon Eclipse Ti inverted microscope.
Similarly expression of IBDV VP2 protein (SEQ ID NO: 8 encoded by SEQ ID NO: 7) of vHVT306 were examined by IFA using chicken anti-IBDV sera (Charles River Laboratories cat # 10100610 Lot # G0117 ) (1:500 dilution) and anti-NDV F monoclonal antibody 001C3 (Asceitic fluid, Lot 10/09/044, 02/11/2010) (1:300 dilution) as primary antibodies; followed by goat anti-chicken IgG with fluorescein (KPL cat # .02-24-06, lot # 11020) (1:500 dilution) and donkey anti-IgG-Alexa Fluor 568 (Molecular Probe # A10037, lot #989784) (1:300 dilution) as secondary antibodies.
[0099] By IFI, they indicate that vHVT306 expresses the NDV F genes in virus-infected CEFs.
[0100] More than 400 vHVT306 plates were counted using the FITC filter and TRITC-microscope filter. General expression of the NDV F and IBDV VP2 gene pool with the HVT plates (Table 5). Table 5 - Double IFA of vHVT306
Southern Blot Analysis
[0101] Total genomic DNA was extracted from pre-vHVT306 MSV infected CEF material. Southern blot analysis was performed according to standard protocol.
[0102] A total of three probes were used to confirm the NDV F cassette (SV40 promoter, NDV F codon of the optimized gene, synthetic polyA tail) between SORF3 and US2 of vHVT306 as well as the retention of the VP2 IBDV cassette (mCMV promoter, the IBDV VP2 gene, SV40 poly A tail).
[0103] The Southern blot results showed the digestion patterns as expected based on the NTI Vector (Invitrogen, 1600 Faraday Ave., Carlsbad, CA) map analysis. The NDV F cassette (SV40 promoter, codon optimized NDV F, synthetic poly A tail) is located between SORF3 and US2, and VP2 IBDV cassette (mCMV promoter, IBDV VP2 gene, SV40 poly A tail) is intact as the parent virus (vHVT13). genomic analysis
[0104] Genomic DNA from pre-MSV stock vHVT306 was sequenced to verify the recombination region arm sequence as well as the gene inserted into the cassette.
[0105] The primers were designed to amplify the entire inserted gene cassette, including the recombination arm used in the donor plasmid. Analysis of vHVT306 genomic DNA was performed by PCR amplification, followed by nucleotide sequence determination.
[0106] The vHVT306 (donor plasmid pHVT US2 SV-Fopt-synPA) containing the recombination arms, the SV40 promoter and the codon optimized NDV F gene was confirmed to be correct as shown in SEQ ID NO: 20. Western blot analysis
[0107] The CEF monolayer was infected with pre-MSV vHVT306 at MOI - 0.1. After a four day incubation, the CEFs were pelleted and washed with PBS, followed by lysis with IP Lysis Buffer/Wash Kit from Classic IP Pierce (Thermo Scientific cat # 26146) according to the manufacturer's protocols. The lysate was pre-cleaned and incubated with 100 μl of anti-NDV F 001C3 monoclonal antibody to make the immune complex. The immune complex was captured by Protein A/G Plus agarose and after removing the unlimited immune complex by washing steps, 50 μl of sample buffer was used to elute under non-reducing conditions. Uninfected CEFs were included as controls. 20 ul of the eluted samples were separated into 10% Bis-Tris Gels by electrophoresis. After electrophoresis, the separated proteins were transferred to a PVDF membrane. The Protein Detection TMB Western Blot Kit (PL cat # 54-1-1-50) was used to detect NDV antigens on PVDF membrane with anti-NDV chicken serum (Charles River Laboratories Laboratories lot # 10.100.641, lot # C0117A ), and goat anti-chicken IgG-peroxidase conjugate (KPL cat # 14-24-06) following manufacturers protocols.
[0108] The expression of the NDV F protein of vHVT306 was confirmed by two steps of immunodetection. First, NDV F proteins expressed from vHVT306 CEF infected were captured by immunoprecipitation using anti-NDV F antibodies monoclonal antibody 001C3. Western blot analysis using subsequently polyclonal NDV antiserum (Charles River Laboratories cat # 10100641, lot # C0117 A) was used for the detection of NDV F protein in the captured samples (antibody-NDV F monoclonal protein complexes) ( Fig. 8). A 55 kDa protein in the pre-vHVT306 MSV lysates was detected by the NDV antiserum which corresponds to the expected size of the F1 NDV fusion protein (Fig. 8). Example 4 Construction of HTV double vectors vHVT301, vHVT302, vHVT303, VHVT304 and vHVT307 expressing NDV-F and IBDV VP2, and give a double vector HVT vHVT202 expressing IBDV VP2 variants Example 4.1 Construction of vHVT301, vHVT302, vHVT303, VHVT304 and vHVT307
[0109] Generation and characterization of recombinant dual HVTs vHVT301, vHVT302, vHVT303, vHVT304, and vHVT307 were performed in essentially the same way as for vHVT306 described in example 3. Table 6.1 shows the unique characteristics for each construct around the expression cassettes, including the respective sequences. Table 6.1 Characteristics of double recombinant HTV expression cassettes
vHVT301
[0110] Plasmid pHVT IG2 Sbfl (material owned by Merial), containing Intergenic arms 2 sequences from vHVT13 which was digested with Smal, dephosphorylated, and the 4.3kb fragment was gel extracted. Donor plasmid pHM103 + NDV-F by weight containing an SV40 promoter, wild type NDV-F wild type NDV-F genotype Vlld, SV40 tail poly A was digested with EcoRI and Sail, treated with Klenow and the 2.3 fragment kb gel was extracted. The two fragments were ligated to create a donor plasmid pHVT IG2 SV FWT SbfI (SEQ ID NO: 24) used in trans infection to generate recombinant vHVT301.
[0111] A synthetically synthesized plasmid, pHVTUS10 cds, containing US10 arm sequences of vHVT13 was digested with NotI, dephosphorylated, and the 4.7kb fragment was gel extracted. A 1.7 kb fragmented NotI fragment of a chemically synthesized, codon-optimized NDV-F V11d genotype was NotI digested and gel extracted. The two fragments were ligated to create a pHVT USA donor plasmid 10 cds F opt used in transfection to generate recombinant vHVT302. Transcription of the inserted F gene must be driven by the native US10 promoter and be terminated by the native US10 polyA signal. No exogenous promoter or polyA is added to express this insert. Insertion region sequencing confirmed that vHVT302 contains the correct sequence of the NDV-F Vlld gene with optimized codons, as shown in donor plasmid sequence pHVT US10 cds opt F (SEQ ID NO: 25). VHVT303
[0112] The synthetically synthesized plasmid pHVT US10 cds containing the US10 arm sequences of vHVT13 was digested with NotI, dephosphorylated, and the 4.7kb fragment was gel extracted. NotI flanked by a 1.7 kb fragment of a chemically-optimized, codon-optimized NDV-F genotype V, NotI was digested and gel extracted. The two fragments were ligated to create a donor plasmid pHVT US10 cds F CA02 opt used in transfection to generate recombinant vHVT303. As with vHVT302, transcription of this inserted F gene must also be driven by the native US10 promoter and be terminated by the native US10 polyA signal. No exogenous promoter or polyA is added to express this insert. Insertion region sequencing confirmed that vHVT303 contains the correct sequence of the NDV-F genotype V optimized codons as shown in donor plasmid pHVT sequence US10 cds F CA02 (SEQ ID NO: 26). vHVT304
[0113] Donor plasmid pHVTIG2SbfI containing two Intergenic sequences from vHVT13 arm was digested with SbfI, dephosphorylated, and the 4.3 kb fragment was gel extracted. A synthetically synthesized plasmid containing an SV40 promoter + NDV-F Vlld genotype optimized codons + Sbfl flanked synthetic polyA tail was digested with SbfI and the 2.3kb fragment was gel extracted. The two fragments were ligated to create a pHVTIG2SV Fopt syn tail donor plasmid used in transfection to generate recombinant vHVT304. Insertion region sequencing confirmed that vHVT304 contains the correct SV40 promoter sequences, the codon optimized NDV-F Vlld gene, and the synthetic poly A tail, as shown in donor plasmid sequence pHVT IG2 SV Fopt syn tail ( SEQ ID NO: 27). vHVT307
[0114] The pHVT donor plasmid US2-SORF3 containing the SORF3 and US2 arm sequences of vHVT13 was digested with SbfI, dephosphorylated, and the 5.1kb fragment was gel extracted. The SB-1 plasmid UL55 SV CaF syn SbfI tail containing an SV40 promoter + NDV-F genotype V optimized codons + SbfI flanked synthetic polyA tail was digested with SbfI and the 2.3kb fragment was gel extracted. The two fragments were ligated to create a donor plasmid pHVT US2 SV-FCA02 opt-synPA used in transfection to generate recombinant vHVT307. Insertion region sequencing confirmed that vHVT307 contains the correct sequences of the SV40 promoter, the codon optimized NDV-F gene Vlld, and the synthetic poly A tail, as shown in donor plasmid sequence pHVT US2 SV-FCA02 opt- synPA (SEQ ID NO:28). Discussion
[0115] One of the main objectives of this work was to develop a multivalent avian vector based on Herpesviruses, incorporating several protective genes of interest for an avian Herpesvirus main chain (eg HVT). A prerequisite for this approach is to define expression cassettes containing appropriate promoter-gene-poly-combinations and assess their genetic stability and ability to protect against specific disease.
[0116] For the purpose of creating an effective DM-IBD-ND trivalent vector vaccine, either codon optimized or non-optimized Newcastle Disease Virus (NDV)-F gene sequences have been cloned into the main chain vHVT13 (HVT- DII, a licensed vaccine to simultaneously protect chickens against MD and IBD) under human CMV (CMV mouse is already used in vHVT13). All vHVT-IBD-F constructed under human CMV promoter lost F-protein expression within six passages of whether or not the NDV-F sequence has optimized codons and regardless of insertion site. The loss of protein C expression was rapid (within two passages) when hCMV was combined with codon-optimized F protein, compared to a combination of hCMV with wild-type F sequence (the loss of expression of protein C over time 6 passes). Taken together, the data show that human CMV is not an ideal promoter for the production of stable recombinant HVTs that express the NDV-F protein. Surprisingly, this example shows that the SV40 promoter and the endogenous HVT promoter (US10 promoter) generated stable recombinant HVT that express the NDV-F protein. Example 4.2 Construction of vHVT202 Construction of the HVT Donor Plasmid SORF3-US2 gpVar-Ewtsvn
[0117] A fragment encompassing the wild-type synthetic Variant E of the IBDV VP2 gene (SEQ ID NO: 41 encoding SEQ ID NO: 42) was excised from pUC57 Varient E plasmid in weight (synthesized by GeneScript) using NotI and inserted into the same SORF3 and US2 site as the plasmid containing gpCMV promoter and a synthetic poly A tail. Bound material was transformed using Top 10 Oneshot kit (Cat # C404002, Invitrogen). Bacterial colonies were grown in LBamp broth, plasmid extracted using Qiagens MiniSpin Prep kit, and screened for insertion orientation using HindIII + Saci digestion. The correct donor plasmid was designated pHVT SORF3-US2 gpVar-Ewt Syn. Table 6.2 shows the unique features for building around the expression cassettes, including their sequences. Large-scale cultures were developed and plasmid extraction was performed using Qiagens Maxi Prep kit. Transient expression of maxi preps was verified using Fugene Transfection Reagent in chicken embryo fibroblast cells (CEF's) and chicken polyclonal sera against IBDV. Table 6.2 - Characteristics of double recombinant HVT expression cassettes
Recombinant Generation
[0118] A standard homologous recombination procedure was followed by co-electroporation of secondary CEF cells using donor plasmid pHVTSORF3-US2 gpVar-Ewt Syn and viral DNA isolated from vHVT306 and digested with SbfI. vHVT306, expressing VP2 of classic IBDV and NDV-F, was chosen as a parent to simplify the slicing process as described below. The E VP2 donor plasmid variant was designed to replace the F gene and recombinants were initially selected by absence of F gene expression and then by PCR to detect the presence of the E VP2 variant. Co-electroporation was performed with l x 107 2° CEF in 300 l Opti-MEM and shocked to 150 volts with 950 capacitance in a 2 mm electroporation cuvette. Transfected cells were seeded in 96-well plate and incubated for 5-7 days. Cells grown in 96-well plates were then repeated in two 96-well plates and incubated for a further 5 days. One set of 96-well plates was used for IFA using polyclonal chicken sera against NDV-F to identify positive wells containing the parental vHVT306 and another set of 96-well plates was used to recover infected cells from the IFA negative wells.
[0119] Recombinant virus purification methods were performed first by 96-well plate duplication and IFA selection for the wells containing the most negative IFA plates (against NDV-F) with the least amount of positive IFA plates. Wells matching these criteria were then harvested and adjusted to 1 ml DMEM + 2% FBS. From the stock 1ml 5 - 20 l (depending on the number of visible plaques) were removed and mixed with 1 X 107 CEFs in 10 ml DMEM + 2% FBS and aliquoted to a new 96-well plate in one trial to have individual HVT plates per well. The 96-well plates were duplicated after 4 days of incubation and the wells containing the plates were tested for the presence of recombinant HVT and absence of parental virus by IFA and by PCR. Again the wells that appear to have more recombinant virus and less parental virus, by comparing PCR band results, were collected and adjusted to 1 ml and aliquoted into new 96-well plates (same as before). After five rounds of purification of virus-infected cells, recombinant HVT containing two IBDV VP2 proteins was isolated and the purity of the recombinant virus was tested by PCR to confirm the absence of parental virus.
[0120] Sequencing of the insertion region confirmed that vHVT202 contains the correct sequences of the guinea pig CMV promoter, the wild-type IBDV E variant VP2 gene, and the synthetic poly A tail, as shown in the sequence of the donor plasmid HVT SORF3- US2-gpVar Ewtsyn (SEQ ID NO:39). PCR Recombination Analysis
[0121] DNA was extracted from a virus stock by phenol/chloroform extraction, ethanol precipitated and resuspended in 20 mM HEPES. PCR primers were specifically designed to identify the E Varient gene in weight, promoter, polyA, as well as the purity of the recombinant virus from the parental HVT virus. PCR was performed using 200 ug of template DNA together with the specific primer pairs indicated in table 1, PCR cycling conditions are as follows (unless otherwise indicated): From 94°C - 2 min ; 30 cycles of 94°C - 30 seconds, 55°C - 30 seconds, 68°C - 3 min; 68°C - 5 min.
[0122] The purity of the recombinant viruses was verified by PCR using the primer pairs that are specific for the flanked HVT arms, the gpCMV promoter, the Varient E gene and the syn tail. Primers, specific for SB1, MDV serotype 2 (SB1US1.FP + SBlSorf4.RP) were also included in the analysis. PCR results demonstrate that recombinant virus vHVT202 carries the desired expression cassette and the virus stock is free of detectable amounts of parental HVT virus. Immunofluorescence staining of vHVT202 recombinant virus expressing two IBDV VP2 proteins
[0123] For immunofluorescence tests, the P3 material was diluted 1:100 in medium. Approximately 50 µl of the diluted virus was added to 10 ml of DMEM + 2% FBS with 1 x 107 CEFs and then aliquoted into a 96-well plate (100 µl/well). Plates were incubated for 4 days at 37°C, 5% CO 2 until viral plaques were visible. Plates were fixed with 95% ice-cold acetone for three minutes and washed three times with PBS. A well was used for the Newcastle Disease Virus chicken antisera (lot # C0139, Charles Rivers Laboratory) where 1:1000 was added and the plates were incubated at 37°C for 1 hour. The other was also used for chicken antisera against IBDV (lot # G0117) After one hour of incubation, plates were washed three times with PBS and FITC anti-chicken (cat # F8888, Sigma) was added to 1: 500. Again, plates were incubated at 37°C for 1 hour. After one hour of incubation, cells were washed three times with PBS and visualized with a fluorescent microscope using fluorescein isothiocyanate (FITC) filter.
[0124] The results of immunofluorescence staining indicate that vHVT202 exhibited very strong VP2 protein expression when polyclonal sera against both classical and variant VP2 E proteins were used. Conclusion
[0125] Based on PCR and immunofluorescence analysis, vHVT202 is a recombinant HVT, in which an E variant IBDV VP2 gene under the control of the gpCMV promoter has been successfully introduced into a recombinant HVT base that already expresses the gene of Classic IBDV VP2. Consequently vHVT202 carries two E-variant and classical IBDV genes VP2 and is free of any detectable parental vHVT306 virus. Example 5 Construction of vSB1-009, vSB1-004, vSB1-006, vSB1-007, vSB1-008, and vSBl-010 recombinant expressing NDV-F Example 5.1 Construction of vSB1-009, vSB1-004, vSB1-006, vSBl - 007, and 008-vSBl
[0126] The aim of this study is to construct a recombinant viral vector VSB 1-009 of SB-1, in which an expression cassette containing the SV40 promoter and the Newcastle disease virus fusion protein (NDV-F) ) is introduced to replace the UL44 (gC ) coding sequence of SB-1.
[0127] A PSBL 44 cds SV FCAopt donor plasmid was constructed containing UL44 arms flanked by SB1 virus, the SV40 promoter and the optimized gene NDV F codon sequence (SEQ ID NO: 5, which codes for SEQ ID NO: 6). Generation of Recombinant Viruses
[0128] A standard homologous recombination procedure was followed by co-electroporation of secondary CEF cells using PSBL donor plasmid 44 cds SV FCAopt and viral DNA isolated from virus SB-1 infected CEFs. Essentially, the procedure described in example 1 for vHVT114 was followed to generate, purify and characterize recombinant plaques by immunofluorescence.
[0129] After five rounds of plaque purification, pure recombinant virus (VSB 1-009) was isolated and the purity of VSB 1-009 was tested by IFA and PCR to confirm proper insertion as well as no parental virus remaining. PCR analysis
[0130] Viral DNA was extracted from VSB 1-009 pre-master virus seed (pre-MSV) stock by QIA DNeasy Blood & Tissue Kit (Qiagen cat #69506). PCR primers were designed to identify the presence of optimized NDV F, wild type NDV F, SV40 promoter, mCMV promoter, UL44 flanking arms of SB-1 and HVT virus. PCR amplifications were performed using about 200 ng of DNA template along with the primer pairs.
[0131] PCR amplification with different primers confirmed that vSBl-009 has the expected amplification patterns and amplicons. Expression Analysis
[0132] Indirect immunofluorescence (IFI) was performed on pre-MSV VSB 1-009 stock to examine the expression of NDV F gene and SB-1 virus antigen. CEFs that were inoculated with 1-009 VSB were fixed with ice cold 95% acetone for three minutes at room temperature and for 10 min, air dried. Plates were washed with PBS, then two primary antibodies anti-chicken Newcastle disease viris serum (Charles Rivers Laboratories cat # 10100641, lot # C0117A) at 1:500 and monoclonal antibody dilution against Y5.9 Virus SB-1 (Merial Select, Gainesville, GA) at 1:3000 dilution was added and the plates were incubated for 45 min at 37°C. After three washes with PBS, two secondary goat anti-IgG antibodies. chicken with fluorescein (KPL cat # .0224-06, lot # 10020 l) at 1:500 dilution and donkey anti-mouse IgG-Alexa Fluor 568 (Molecular Probe # A10037, lot # 989784) at 1:250 dilution have been added. Plates were incubated at 37°C for 45 min and followed by three washes with PBS. Wells were examined for IFA positive plates with a fluorescent microscope using fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC)-Nikon Eclipse Ti filters inverted microscope. Similarly, the reactivity of VSB 1-009 with NDV F Mab was analyzed by double IFA using MDV antiserum (Charles River Laboratories, cat # 10100628, lot # D0111) (1/300) and anti monoclonal antibody dilution. -F of NDV (1/300 dilution) as primary antibody. Goat anti-chicken with IgG-fluorescein (KPL cat # .02-24-06, lot # 10020) (1:500 dilution) and donkey anti-IgG-Alexa Fluor 568 (Molecular Probe # A10037, lot # 989784 ) (1:250 dilution) were used as secondary antibodies. The wells were observed to identify IFA positive plaques with a fluorescent microscope using Nikon-FITC and TRITC-filters from Nikon Eclipse Ti inverted microscope.
[0133] the results indicate that IFA VSB 1-009 expresses the F protein of NDV in virus-infected CEF. More than 500 VSB 1-009 plaques were counted for NDV F protein expression as well as SB-1 specific protein expression with double IFA virus. The expression of the NDV F protein completely combined with the expression of the SB-1 virus antigen on each virus plate (Table 7). Table 7 - vSB1-009 Dual IFA

[0134] NDV F Mab reactivity was confirmed by double IFA. More than 200 VSB-1-009 plates were examined for NDV F Mab reactivity as well as anti-MDV serum reactivity. Reactivity with NDV F Mab completely combined with reactivity of anti-MDV serum on each virus plate (Table 8). Reactivity of VSB 1 -009 with anti-ND VF Mab
Southern Blot Analysis
[0135] Total genomic DNA was extracted from VSB 1-009 pre-MSV from infected CEF stocks. Genomic DNA from VSB 1-009, virus SB-1 (negative control), 44 PSBL cds SV FCA opt donor plasmid were digested at 37°C, with EcoRI, NcoI, and Kpnl restriction endonucleases separately. Restriction fragments were separated by 0.8% agarose gel electrophoresis and transferred to a positively charged nylon membrane. After transfer, the membrane was treated with 0.4 M NaOH and then neutralized with 2 X SSC-HC1 buffer. The membrane was then air dried and UV cross-linked.
[0136] After hybridization and Nortfi2South Chemiluminescent Detection Kit (Thermo Scientific cat #89880) according to the manufacturers instructions, the membrane was prehybridized for 1 hour and then hybridized with the probe at 55 °C overnight. For hybridization, two probes were used; 1) the Sbfl fragment from PSBL 44 cds SV FCA opt as the NDV F cassette probe, 2) the SmaI-EcoRI fragment from pUC57 SB1 44 arm (GenScript) as an arm recombination probe. After overnight hybridization, several stringency washes were conducted until the membrane was placed in a blocking buffer, with the addition of Streptavidin-HRP. After washing the membrane of any uncoupled Streptavidin-HRP, the luminal substrate solution and peroxide were added. The membrane was then exposed to X-ray film and the membrane was developed.
[0137] Southern blot results were as expected based on NTI Vector map analysis. The NDV F cassette (Promoter SV40, codon optimized gene NDV-F CA02) replaced the UL44 coding sequences of the SB-1 virus. genomic analysis
[0138] Genomic DNA of VSB 1-009 pre-MSV material was performed by determining the nucleotide sequence of the recombination region of the arm as well as inserted gene cassettes. Primers were designed and used to amplify the entire NDV-F gene cassette, including the recombination arms.
[0139] The vSB1-009 sequence (plasmid donor pSB1 44 cds SV FCAopt) containing the recombinant arms, SV40 promoter and gene-optimized NDV F codon has been confirmed to be correct as shown in SEQ ID NO:19. Western blot analysis
[0140] The CEF monolayer was infected with VSB 1 -009 pre-MSV at MOI - 0.1. After a 5 day incubation, the CEFs were pelleted and washed with PBS, followed by lysis with IP kit lysis buffer/water of classic IP pieces (Thermo Scientific cat # 26146) according to the manufacturers protocols. The lysate was pre-cleared and incubated with 100 µl of NDV anti-F monoclonal antibody to make the immune complex. The immune complex was captured by protein A/G Plus agarose and after removal of the immune complex bounded by washing steps, 50 l of sample buffer was used to elute under non-reducing conditions. Uninfected CEFs were included as a control. 20 l of eluted samples were separated on 10% Bis-Tris gel by electrophoresis. After electrophoresis, the proteins separated in the gel were transferred to a PVDF membrane. The Protein Detection TMB Western Blot Kit (KPL eat # 54 - 11-50) was used to detect the NDV antigens to PVDF membrane with chicken anti-NDV serum (Charles River Laboratories Laboratories cat # 0100641 l, lot # C0117A) and goat anti-chicken IgG-peroxidase conjugate (KPL cat # 14-24-06) following manufacturers protocols.
[0141] The expression of the NDV F protein of VSB1 -009 was confirmed by two steps of immunodetection. First, NDV F proteins expressed from VSB 1-009 infected CEF lysate were captured by immunoprecipitation using anti-NDV F antibodies monoclonal antibody 001C3. Western blot analysis using subsequently polyclonal NDV antiserum (Charles River Laboratories cat # 10,100,641, lot # C0117 A) was used for the detection of NDV F protein in the captured samples (antibody-NDV F monoclonal protein complexes ) (fig. 9). A protein of about 55 kDa in lysed VSB 1-007 pre-MSV was detected by anti-NDV serum which corresponds to the expected size of the F1 NDV fusion protein (Fig. 9).
[0142] Generation and characterization of recombinant HVTs vSB1-004, vSB1-006 1, vSB1-007 and vSB1-008 were done essentially the same way as for VSB1-009 described in this example. Table 9.1 shows the unique characteristics of each construct around the expression cassettes, including their sequences. The generation and characterization of recombinant SB viral vectors has also been described in U.S. Patent Application No. US 13/689,572 filed November 29, 2012 (Merial Limited), which is incorporated herein by reference in its entirety. Table 9.1 - Characteristics of recombinant SB1 expression cassettes
Example 5.2 - Construction of the double construct vSBl-010 Donor Plasmid Construct SB1US2 gpVIIdwtsyn
[0143] Using the plasmid HVT SOrf3-US2 gpVar-Ewt Syn, the gpCMV, Varient E, Syn tail was removed by SbfI digestion. This fragment was ligated to donor plasmid SB1 US2. The Varient E gene was cut by Notl and replaced by NDV-F Vlld wt. The wild type NDV-F Vlld synthetic gene (SEQ ID NO:3 encoding SEQ ID NO:4) was excised from plasmid pUC57 NDV-F Vlld wt (synthesized by GeneScript) using NotI digestion. Bound material was transformed using Top 10 Oneshot kit (Cat # C404002, Invitrogen). Bacterial colonies were grown in LBamp broth, plasmid extracted using Qiagens MiniSpin Prep kit, and screened for insertion orientation using Ncol + Sall digestion. The correct donor plasmid was designated PSBL US2 gpVlldwt Syn. Table 9.2 shows the unique features for building around expression cassettes, including their sequences. Large-scale cultures were developed and plasmid extraction was performed using Qiagens Maxi Prep kit. Transient expression of maxi preps was verified using Fugene Transfection Reagent in chicken embryo fibroblast cells (CEF's) and chicken polyclonal sera against NDV-F. Recombinant Generation
[0144] A standard homologous recombination process was followed by co-electroporation of secondary CEF cells using donor plasmid PSBL US2 gpVIIdWt Syn and viral DNA isolated from vSB1-009 (vSB1-009 is already a recombinant virus expressing the CA02 gene F of NDV). Essentially, the procedure described in example 1 for vHVT114 was followed to generate, purify and characterize recombinant plaques by immunofluorescence.
[0145] After five rounds of plaque purification, pure recombinant virus (vSB1-010) was isolated and the purity of vSBl-010 was tested by IFA and by PCR to confirm the proper insertion as well as no parental virus remaining. Table 9.2 VSBl-010 Expression Cassette Characteristics

[0146] Sequencing of the insertion region confirmed that vSB 1-010 contains the correct guinea pig CMV promoter sequences and the NDV-F gene Vlld wt as shown in donor plasmid sequence SB1US2 gpVIIdwtsyn (SEQ ID NO: 40) . PCR Recombination Analysis
[0147] DNA was extracted from a virus stock by extraction with phenol / chloroform, ethanol precipitated and resuspended in 20 mM HEPES. The PCR primers were specifically designed to identify the NDV-F Vlld wt gene, the promoter, the poly A, as well as the purity of the recombinant virus from SB1 parental virus. PCR was performed using 200 μg of template DNA, together with the indicated primer pairs indicated in Table 1. PCR cycling conditions are as follows (unless otherwise indicated): from 94°C - 2 min ; 30 cycles of 94°C - 30 seconds, 55°C - 30 seconds, 68°C - 3 min; 68°C - 5 min.
[0148] The purity of the recombinant viruses was verified by PCR using the primer pairs that are specific for the SB1 flanking arms, the gpCMV promoter, the NDV-F wt Vlld gene and the syn tail. Primers, specific for HVT, MDV serotype 3 (MB080 + MB081) were also included in the analysis. The PCR results demonstrate that the recombinant virus vSB1-010 carries the desired expression cassette and the virus stock is free of detectable amounts of parental virus SB1-009. Immunofluorescent staining of vSBl-010 recombinant virus expressing two NDV-F proteins
[0149] For immunofluorescence tests, the P3 material was diluted 1:100 in medium. Approximately 50 l of the diluted virus was added to 10 ml of DMEM + 2% FBS with 1 x 107 CEFs and then aliquoted into a 96-well plate (100 l/well). Plates were incubated for 5 days at 37°C, 5% CO 2 until viral plaques were visible. Plates were fixed with 95% ice-cold acetone for three minutes and washed three times with PBS. Chicken antisera against Newcastle disease virus (lot # C0139, Charles Rivers Laboratory) at 1:1000 was added and the plates were incubated at 37°C for 1 hour. After one hour of incubation, plates were washed three times with PBS and FITC anti-chicken (cat # F8888, Sigma) was added at 1:500. Again, plates were incubated at 37°C for 1 hour. After one hour of incubation, cells were washed three times with PBS and visualized with a fluorescent microscope using fluorescein isothiocyanate (FITC) filter.
[0150] Immunofluorescent staining results indicate that vSBl-010 exhibited very strong NDV-F protein expression when polyclonal serum was used against both NDV proteins CA02 and Vlld F. Conclusion
[0151] Based on PCR tests and immunofluorescence analysis, vSBl-010 is a recombinant SB-1, in which the NDV dF gene VII under the control of the gpCMV promoter was successfully introduced into a vSB1-009, which already expresses the NDV gene CA02-F. Consequently vSB1-010 carries genes from both the Vlld and CA02 F genotypes of NDV and is free of any detectable parental VSB 1-009. Example 6 - Efficacy of vHVT110, vHVT111, vHVT114 and vSB1-004 expressing the NDV F gene against challenges with NDV strains from Chimalhuacan and Malaysia (MAL04-01), at 14 days of age in SPF chickens
[0152] The aim of the study was to evaluate the efficacy of three recombinant HVT constructs (vHVTl10, vHVT111 and vHVT114) and a recombinant SB1 construct (vSB1-004) expressing the NDV F gene against the challenges of Newcastle disease (Chimalhuacan virus strains and Malaysia), performed at 14 days of age in SPF chickens.
[0153] The characteristics of these five vaccine candidates are described in Table 10 below. Table 10 - Characteristics of the vectors used in the challenge study

[0154] At OD (zero), 100-day-old SPF chickens were randomly assigned to 10 groups of 10 birds. Birds were injected subcutaneously in the neck on D 0 with 0.2 ml of the recombinant vaccines, containing a target dose of 2000 pfu, as described in Table 11 below. It should be noted that the titer of vSB1-004 (31600 pfu) administered to birds in groups 6 was well above the target. Birds were challenged intramuscularly on D14 with velogenic ND Malaysia strain (genotype Vlld) (subgroups "a") or with virulent strain (genotype V) ND Chimalhuacan (subgroups "b"). Table 11 Challenge study with vHVT 110, vHVT 111, 114 and vHVT VSB 1 -004

[0155] Each group was monitored before and after the challenge. Post-challenge clinical signs were scored by day as follows: healthy / with specific symptoms (ruffled feathers, prostration, stiff neck, tremor) / dead. On D14, serum samples were collected in each group for serology (Newcastle Disease Virus (HI) hemagglutination inhibition test).
[0156] As expected, unvaccinated animals (GLA and GIB) showed no NDV antibody at D14. Low titer seroconversion (HI means titer <0.6 log 10) was obtained in each of the vaccinated groups (subgroups of "a" and "b" from G2 to G5) confirming the accurate vaccine. The number of positive/total birds tested was group dependent and was the highest (90%) in vHVT114 of vaccinated birds (see table above).
[0157] Percentages of protection from mortality and morbidity are reported in the table above. Complete susceptibility was observed in the Gla and Gib control groups, thus validating the high severity of both challenges. Lower levels of protection were observed in groups vaccinated with vHVT111 or VSB 1-004. Higher rates of protection against morbidity and mortality were obtained in the groups vaccinated with vHVT110 or vHVT114 regardless of the challenge strain used (homologous strain, ie Malaysia Vlld genotype or heterologous strain, ie Chimalhuacan genotype V). There was a correlation between the % of birds positive by the HI test before the challenge and the % of protection.
[0158] The difference in protection obtained between vHVTl10 and vHVTl11 clearly illustrates the importance of the promoter, the IE promoter of mCMV being more potent than the SV40 promoter for the transcription of the wild-type (wt) genotype of the F Vlld gene. The difference in protection obtained between vHVTl11 and vHVTl14 illustrates the importance of the nucleotide sequence of the F gene, the optimized sequence being more potent than the wild-type (or native) sequence.
[0159] In conclusion, the results of this study demonstrated the importance of the promoter and the nucleotide sequence of the F gene in the ND protection induced by Marek's disease vector vaccines. An ideal combination of these factors needs to be found to achieve the best efficacy performances as for vHVTl14. Example 7 - Efficacy of vHVT114, vHVT116, vHVT301, vHVT302 and vHVT303 expressing the NDV F gene against challenges with NDV Texas GB strains at 14 days of age in SPF chickens
[0160] The aim of the study was to evaluate the efficacy of 2 single recombinant HVT constructs (vHVTl14 and vHVTl16) expressing the NDV F gene and 3 double recombinant HVT constructs (vHVT301, vHVT302 and vHVT303) expressing both NDV F and VP2 genes IBDV against Newcastle disease challenge (Texas GB strains, genotype II) performed at 14 days of age in SPF chickens.
[0161] The characteristics of these four vaccine candidates are described in Table 12 below. Table 12- Characteristics of the vectors used in the challenge study
* vHVT13 is the active ingredient of the licensed Vaxxitek HVT-DII vaccine based on an HVT vector expressing the IBDV VP2 gene (see US patents 5,980,906 and EP 0 719 864).
[0162] At DO, 120-day-old SPF chickens were randomly assigned to 6 groups of 20 birds. Birds were injected subcutaneously into the neck at the OD with 0.2 ml of the recombinant vaccines, containing a target dose of 1,000 pfu, as described in Table 13 below. Birds were challenged intramuscularly on D14 with 4.5 log 10 of velogenic strain DIO50 ND Texas GB (genotype II). Table 13 - Efficacy Results

[0163] Each group was monitored before and after the challenge. NDV clinical signs and mortality were recorded after challenge.
[0164] The clinical protection percentages are reported in the table above. Complete susceptibility was observed in the unvaccinated G1 challenged control group, thus validating the high severity of both challenges. Partial protection was observed for the five vaccine candidates, with the best performances being obtained with vHVTl14 and vHVTl16. Among the double HVT recombinants, vHVT302 was the most protective. It performs better than vHVT303 suggesting that the optimized genotype of the Vlld NDV F gene may be better cross-protection against genotype II challenge than the optimized genotype of the V NDV F gene. A similar trend was observed with the only HVT, the vHVTl 14 (Vlld gene) performing somewhat better than vHVT116 (V gene), but the difference was less pronounced. These results indicate that both genotypes of the Vlld and V NDV F genes inserted into the HVT vector provide cross-protection against a heterologous genotype II NDV challenge; the Vlld gene may potentially be more cross-protective. vHVT302 induced better protection than vHVT301 ND confirming the importance of promoter, poly-A and insertion locus. In conclusion, the results of this study demonstrated very good early protection of ND induced by tested Marek's disease vector vaccines, in particular for the only tested HVT-ND. Example 8 - Efficacy of vHVT114, vHVT116, vSB1-007, vSB1-008 (alone or with vHVT13) and vHVT304 against challenges with NDV ZJ1 (genotype Vlld) and California/02 (genotype V) at 21 days of age in SPF chickens
[0165] The aim of the study was to evaluate the efficacy of 2 single recombinant HVT constructs (vHVTl 14 and vHVTl 16), 2 SB1 recombinant constructs (VSB 1-007 and VSB 1-008) that express the NDV F gene and a double Recombinant HVT (vHVT304) against Newcastle disease challenge with NDV ZJ1 (Vlld genotype) and California/02 (V genotype) performed at 21 days of age in SPF chickens.
[0166] The characteristics of these five vaccine candidates are described in Table 14 below. Table 14 - Characteristics of the vectors used in the challenge study
*VHVT13 is the active ingredient of the licensed Vaxxitek HVT-DII vaccine based on an HVT vector expressing the IBDV VP2 gene (see US patent 5,980,906 and EP 0 719 864).
[0167] At DO, 158-day-old SPF birds were randomly assigned to 6 groups of 24 birds (vaccinated) and one group of 12 birds (unvaccinated controls). Birds were injected subcutaneously into the neck at the OD with 0.2 ml of the recombinant vaccines containing a target dose of 1,000 pfu, as described in Table 15 below. The birds were then separated into two subgroups, each subgroup being challenged by the intramuscular route on D21 with 5 log 10 EID50 of either the NDV ZJ1 strain (Vlld genotype) or California/02 velogenic strain (V genotype). Table 15 - Efficacy Results

[0168] Each group was monitored before and after the challenge. The technical problems observed with insulators reduced the number of birds in group 2 (vHVTl 14: from 24 to 14) and in group 3 (vHVTl 16: from 24 to 20). NDV clinical signs were recorded after challenge. Serum was collected from blood samples from birds of groups 2 and 7 before challenge (D21) for NDV serology by means of the HI test using strains each challenge as antigen.
[0169] Mean serological IH titers in G2 and G7 before challenge are shown in Figure 10. IH titers were higher with the ZJ1 antigen in both groups. The titers of inhibitory antibodies induced by vHVT1 14 were higher than those induced by vHVT304.
[0170] Percentages of protection from mortality and morbidity are reported in the table above. Complete susceptibility was observed in the unvaccinated G1 challenged control group, thus validating the high severity of both challenges. All vaccines induced high levels (> 75%) of protection against both challenges. Complete clinical protection against both challenges was induced by vHVTl14 and VSB 1-008. Following a similar trend as inhibitor antibody titers, the ND-induced protection of vHVT304 was slightly lower than that induced by vHVT114.
[0171] Protection was assessed after challenge by real-time RT-PCR on oral and cloacal swabs taken 2 and 4 days after challenge. Percentages of positive birds (Ct <40) are shown for the two challenges in FIG. 11A and 11B. Note that all 6 birds were dead at 4 DPCH in the control group challenged with the CA/02 isolate and only one bird (out of 6) was still alive at 4 DPCH in the control group challenged with ZJ1. protection was detected in all control birds. A reduction in the percentage of positive for the protection of birds was observed in all vaccinated groups.
[0172] In conclusion, the results of this study demonstrated very good protection of 3-week-old ND induced by tested Marek's disease vector vaccines. Example 9 - Efficacy of vHVT114, vSB1-007, vSB1-009, vHVT306 and vHVT307 vaccines against challenges with NDV Texas GB strains at 28 days of age in SPF birds.
[0173] The aim of the study was to evaluate the effectiveness of combinations of different Marek's Disease vector vaccines expressing the NDV F gene and/or the VP2 of IBDV against Newcastle disease challenge (Texas GB strain, genotype II) performed at 28 days of age in SPF birds.
[0174] The characteristics of the five recombinant vaccine candidates tested in this study are described in Table 16 below. Table 16 - Characteristics of the vectors used in the challenge study

[0175] Marek's disease virus serotype 1 vaccines (strain CVI988 (or Rispens); herpesvirus Gallid 2) and serotype 2 (strain SB-1; herpesvirus Gallid 3) were also used in combination with the recombinant viruses in some of the groups.
[0176] At DO, 135-day-old SPF birds were randomly assigned to 9 groups of 15 birds. Birds were injected subcutaneously in the neck in the DO with 0.2 ml containing a target dose of 2000 pfu for recombinant vaccines (vSB1-007, vSB1-009, vHVT13, vHVT306, vHVT307, vHVT114), and 1000 pfu for parental strains vaccines for Marek's disease (SB-1 and CVI988). The design of the nine groups is shown in Table 17 below. Birds were challenged intramuscularly on D28 with 4.0 log 10 DIO50 velogenic strain ND Texas GB (genotype II). Table 17 - Efficacy Results

[0177] Each group was monitored before and after the challenge. Clinical signs of NDV were recorded after challenge.
[0178] Percentages of protection from mortality and morbidity are reported in the table above. Complete susceptibility was observed in the unvaccinated G1 challenged control group, thus validating the high severity of the challenge. Excellent levels of protection were observed in all vaccinated groups. Birds in groups G3, G6, G7 and G9 were fully protected. This study shows that vSBl-ND candidates can be co-administered with vHVT13 and CVI988 and still provide very good ND protection. Likewise, dual HVT-DII + ND are compatible with SB-1 and vHVT-ND (vHVTl14) is compatible with vHVT13 and SB-1.
[0179] In conclusion, the results of this study showed the absence of interference on the ND protection induced by vector and parental vaccines from tested Marek's disease. Example 10 - Efficacy of vHVT114, vHVT307, vSB1-007 and vSB1-009 in combination with vHVT13 against challenges with NDV Chimalhuacan strains (Genotype V) at D28 in SPF birds.
[0180] The aim of the study was to evaluate the efficacy of a recombinant HVT construct (vHVTl 14) and 2 recombinant SB1 constructs (vSB1-007 and vSB1-009) expressing the NDV F gene in combination with vHVT-IBD (vHVT13) as well as a double HVT vHVT307 expressing both NDV F and IBDV VP2 against Newcastle disease (Chimalhuacan, genotype V) challenge performed at 28 days of age in SPF birds.
[0181] The characteristics of these four vaccine candidates are described in Table 18 below. Table 18 - Characteristics of the vectors used in the challenge study

[0182] At DO, 45 one-day-old SPF birds were randomly assigned to 4 groups of 10 birds and one group of five birds (unvaccinated control group). Birds were injected subcutaneously into the neck at the OD with 0.2 ml of the recombinant vaccines, containing a target dose of 2000 pfu, as described in Table 19 below. Birds were challenged intramuscularly on D28 with 5.0 log 10 of DIO50 velogenic strain Chimalhuacan (genotype V). Table 19 - Efficacy Results

[0183] Each group was monitored before and after the challenge. NDV clinical signs were recorded after challenge. Oropharyngeal samples were taken from the vaccinated groups at 5 and 7 days after the challenge to assess viral load by real-time RT-PCR.
[0184] Percentages of protection from mortality and morbidity are reported in the table above. Complete susceptibility was observed in the unvaccinated G1 challenged control group, thus validating the high challenge severity. Very good protection was seen in all 4 vaccinated groups, a complete clinical protection being induced by vHVTl 14 + vHVT13.
[0185] The percentage of positive birds and the mean protective titer (expressed as log 10 EID50 equivalents per ml) are shown in FIG. 12A and 12B. Surprisingly, no protection was detected in G2, indicating complete ND protection (against both clinical signs and protection) induced by vHVTl14 even co-administered with vHVT13, under the conditions tested. Protection levels detected in the other vaccinated groups were low, with a slightly higher level detected in G3 (vHVT307) on day 5 post-infection (pi) only.
[0186] In conclusion, this example further illustrates the excellent ND protection induced by double HVT-IBD + recombinant ND or a combination of recombinant SB1-ND or HVT-ND and HVT-IBD (vHVT13) viruses. Contrary to the general belief that the field of a second HVT vaccine (regular HVT vaccines or HVT recombinant vaccines) interferes with immunity to foreign genes inserted in the first recombinant HVT vaccine, the present invention has shown surprising results that vHVT114 in combination with vHVT13 offered excellent protection against NDV and no effect of interference was observed. Example 11 - Efficacy of vHVT306, vSB1-008 in combination with vHVT13 administered by SC or in egg route against challenge with NDV strain Chimalhuacan (genotype V) at D28 in SPF birds.
[0187] The aim of the study was to evaluate the efficacy of dual HVT vHVT306 expressing NDV F and VP2 genes from IBDV, and recombinant VSB 1-008 SB1 expressing NDV F gene in combination with vHVT-IBD (vHVT13), administered by in ovo or subcutaneously against the challenge of Newcastle disease (Chimalhuacan, genotype V) performed at 28 days of age in SPF birds.
[0188] The characteristics of these 2 ND vaccine candidates are reported in table 14 (VSB1-008) and table 16 (vHVT306).
[0189] The design of the groups is shown in Table 20. Sixty embryonated SPF eggs (after about 18 days and 18 hours of incubation; D-3) were used for in ovo administration (20 per group of Gl, G2 and G3 ). Fifty microliters of vaccine containing 2,000 PFU were administered via the in ovo route using the IntelliLab System device from AviTech LLC (Salisbury, MD, USA). Hatchability and survival were recorded after in ovo administration. At DO, 20 one-day-old SPF birds were randomly assigned to two groups of 10 birds (G4 and G5). Birds were injected by (SC) subcutaneous injection into the neck at the OD with 0.2 ml of the recombinant vaccines, containing a target dose of 2000 pfu, as described in Table 20 below. Ten birds per group were challenged intramuscularly on D28 with 5.0 log 10 DIO50 Velogenic Chimalhuacan strain (genotype V). Table 20 - Study model and ND efficacy results

[0190] Each group was monitored before and after the challenge. NDV clinical signs were recorded after challenge. Oropharyngeal samples were taken from the vaccinated groups at 5 and 7 days after the challenge to assess viral load by real-time RT-PCR.
[0191] The total hatchability and viability were recorded until D28 (challenge day) for birds of groups Gl and G2. Hatchability in G3 was 85% and one bird died after hatching in this group. The lower hatching of this group may be due to egg hatcher problems. The body weight of males and females in Gl, G2 and G3 were similar in Dl and D28.
[0192] Percentages of protection against mortality and morbidity are reported in table 20. Complete susceptibility was observed in the unvaccinated G1 challenged control group, thus validating the high challenge severity. Very good protection was observed in all 4 vaccinated groups, complete clinical protection was induced by vHVT306 administered by both routes.
[0193] The percentage of positive birds and the mean protective titer (expressed as log 10 equivalent of EID50 per mL) are indicated in Table 21. No detectable or very low shedding was observed in groups G2 and G4 vaccinated with vHVT306. The protection levels detected in the groups vaccinated with vSBl-008 + vHVT13 were higher especially at 5 days post-infection (pi). Table 21 - Results of protection against change (percentage of birds with detectable change and mean viral load in log 10) evaluated at D5 and D7 after NDV challenge
* Quantitative real-time PCR value, expressed as equivalent of log 10 mean DIO50; the limit is set at 2.7 log 10.
[0194] In conclusion, this example shows excellent ND protection induced by recombinant vHVT306 double HVT administered in ovo or via SC route. The performance of vSBl-008 + vHVT13 was slightly lower, especially after in ovo administration, but this may be at least partially due to problems with the egg incubators. In fact, in ovo safety testing of another recombinant SB1-ND (VSB 1-009) on 1000 or 4000 PFU plus 6000 PFU of vHVT13 did not show any difference in hatchability and early survival with a group that received 6000 PFU of just vHVT13. Example 12 - Efficacy of vHVT304, vHVT306, vSB1-007 and vSB1-008 in combination with vHVT13 against challenge with NDV Chimalhuacan strain (Genotype V) at D42 in commercial broiler birds.
[0195] The aim of the study was to evaluate the efficacy of two double HVTs (vHVT304 and vHVT306) expressing both NDV F and IBDV VP2 genes and two SB1 recombinants (VSB 1-007 and 1-008 VSB) expressing the NDV F gene in combination with vHVT-IBD (vHVT13) against Newcastle disease challenge (Chimalhuacan, genotype V) performed at 42 days of age in commercial broilers.
[0196] The characteristics of these 4 ND vaccine candidates are indicated in Tables 14 and 16. The group models are shown in Table 22. In the DO, 55 one-day-old commercial broilers were randomly allocated to 5 groups of 11 birds . Birds were injected by subcutaneous (SC) injection into the neck at the OD with 0.2 ml of the recombinant vaccines, containing a target dose of 2000 pfu, as described in Table 22 below. Ten birds per group were challenged intramuscularly on D42 with 5.0 log 10 in DIO50 of velogenic Chimalhuacan strains (genotype V). Table 22 - Study design and efficacy results ND

[0197] Each group was monitored before and after the challenge. NDV clinical signs were recorded for 14 days after challenge. Oropharyngeal samples were taken from the vaccinated groups at 5 and 7 days after challenge to assess viral load in real-time RT-PCR.
[0198] Percentages of protection against mortality and morbidity are reported in table 22. Complete susceptibility was observed in the unvaccinated G1 challenged control group, thus validating the high severity of challenge. Very good protection was observed in all 4 vaccinated groups, complete clinical protection is being induced by vHVT306 and by vSBl-007 + vHVT13.
[0199] The percentage of positive birds and the mean titer change (expressed as log 10 EID50 equivalents per ml) are shown in Table 23. The best reduction in protection was induced by vHVT306 and vSBl-007 + vHVT13, which were also the best candidate for clinical protection. Table 23 - Results of protection against change (percentage of birds with detectable change and mean viral load in log 10) evaluated at D5 and D7 after NDV challenge (pi)
* Quantitative real-time PCR value, expressed as mean equivalent log lo DIO50; the limit was set at 2.7 log 10.
[0200] The vHVT306 ND protection was found to be better than that of vHVT304. These two double HVTs contain the same NDV F expression cassette, but inserted at two different loci, which allows IBDV VP2 to be inserted at the same position. Therefore, this example illustrates the importance of the insertion locus in the design of recombinant HVTs. vSBl-007 + vHVT13 was better than vSBl-008 + vHVT13. The genomic structure of vSBl-007 differs from that of VSB1-008 in different aspects: insertion locus, promoter, polyadenylation signal and F gene origin. The combination of these foreign sequences and insertion locus in vSB1-007 were probably responsible for its best results ND protection performances.
[0201] In summary, this example illustrates the importance of the insertion site and other regulatory sequences of the NDV expression cassette in the HVT and MDV-induced ND protection of serotype 2 vectors. Example 13 - Efficacy of dual HVT + IBD-ND (vHVT304 and vHVT306) or SB1-ND (vSB1-008) in combination with vHVT13 recombinant vaccines against challenge with a classic IBDV isolated on D14 in SPF birds
[0202] The aim of the study was to evaluate the early IBD efficacy of dual HVT recombinants vHVT304 and vHVT306, as well as that of vHVT13 co-administered with a SB1-ND recombinant construct (VSB1-008) against a challenge to bursal infectious disease virus virulent (vIBDV) (Faragher strain 52/70 strain), performed at 14 days of age in SPF birds.
[0203] The characteristics of the recombinant double HVT and SB1 used in this study are presented in Tables 14 and 16.
[0204] At DO, 95 one-day-old SPF birds were randomly assigned to 9 groups of 10 birds and one group of five birds (unvaccinated control group). Birds were injected subcutaneously into the neck at the OD with 0.2 ml of the recombinant vaccines, containing a target dose of 300 or 1000 pfu as described in Table 24 below. On D14, a blood sample was collected from five birds per group for serological tests ® with the Kit ProFLOK ® plus IBD (Symbiotic Corp). Birds (10 birds per group, except for group 7, where 1 bird died prior to challenge) were challenged with eye drops (0.05 mL per bird) on D14 with 2.5 log 10 DIO50. Table 24 - Study design and IBD efficacy results
1 mean titres + ELISA IBD, expressed as log 10 in the serum of 5 animals per group sampled at D14 before challenge; 2 birds sick for more than 2 days or still sick on D25 were considered as sick. 3 Protection against clinical signs and severe bursal injury (bursal score < 3) 4bursal weight / body weight ratio of the unvaccinated / unchallenged group was 0.0047.
[0205] Each group was monitored before and after the challenge. Clinical signs of IBDV were recorded for one day after challenge (from D15 to D25). At the end of the post-challenge observation period (D33), all surviving birds were sacrificed and autopsied. Body and bursal weights were recorded. Each Fabricio bag (BF) was weighted then stored in individual containers containing 4% formaldehyde for histology. Bursa histological lesions were scored according to the scale shown in Table 25. Table 25 - Fabrício bursa histological lesions scoring scale
*From Monograph No. 01/2008: 0587 of the European Pharmacopoeia “Avian infectious Bursal Disease vaccine” (live).
[0206] A bird was considered to be affected if it died and/or demonstrated notable signs of disease and/or severe lesions of the bursa of Fabricius (ie histology score >3).
[0207] A significant DII+ ELISA antibody titre expressed in log 10 before challenge is shown in Table 24. Significant titres were detected in all vaccinated groups that were significantly higher than that of the Gl control group. serology was not dose-dependent.
[0208] Severe clinical signs were observed after challenge in all birds in the Gl control group. Seven out of 10 birds in this group died within the 11-day observation period, indicating the high severity of the challenge. None of the vaccinated animals showed severe clinical signs after the challenge, except for one bird from G4 that died. Percentages of protection against severe bursal injuries are shown in the table above. Significant IBD protection was observed in all groups, the best protection being observed in G2 and G3 (vHVT13 alone). Co-administration of vSBl-008 + vHVT13 and the dual constructs vHVT304 and vHVT306 induced similar levels of IBD protection. Protection was not dose-dependent at the doses tested. Mean bursal/body weight ratios are also shown in Table 24. Coefficients in all vaccinated groups were higher than those in the challenged control group.
[0209] In conclusion, these data indicate that the combination of an SB1-ND vector with a single HVT-IBD or dual HVT expressing NDV-F and -IBDV VP2 induced IBD antibodies and early DII protection in an IBDV challenge model serious. Example 14 - Efficacy of single HVT-ND (vHVT114) or SB1-ND (vSB1-007 and vSB1-009) in combination with vHVT13 recombinant vaccines, against challenge with a very virulent IBDV isolated at D23 in commercial broiler chickens.
[0210] The aim of the study was to evaluate the efficacy of IBD vHVT13 co-administered with a recombinant construct (VSB 1-007 and 1-009) VSB against a challenge to the highly virulent infectious virus HVT-ND (vHVTl 14) or SB1- ND O of bursal disease (wIBDV) (91 - 168/980702), performed at 23 days of age in commercial broiler chickens.
[0211] The characteristics of these four vaccine candidates are described in Tables 14 and 16. In the DO, 90 one-day-old broiler chickens were randomly assigned to 7 groups of 12 birds and one group of 6 birds (uncontested unvaccinated control group ) . Birds were injected subcutaneously in the neck at the OD with 0.2 ml of the recombinant vaccines containing a target dose of 3,000 pfu, as described in Table 26. At D14, blood sample was collected from 5 birds per group for tests ® Serum from 10 additional one-day-old chickens was tested to view with the same kit to assess the level of maternal IBDV antibodies. Birds (10 birds per group) were challenged with eye drops (0.05 mL per bird) at D23 with 4.3 log 10 EID50 of the wIBDV 91-168 isolate.
[0212] Each group was monitored before and after the challenge. Clinical signs of IBDV were recorded for 11 days after challenge (from D23 to D33). At the end of the post-challenge observation period (D33), all surviving birds were sacrificed and autopsied. Body and bursal weights were recorded. Each Fabricio bag (BF) was weighted then stored in individual containers containing 4% formaldehyde for histology. The histological lesions of the bursa were scored according to the scale shown in Table 25.
[0213] A bird was considered to be affected if it died and/or showed overt signs of disease and/or severe lesions of the bursa of Fabricius (ie histology score > 3). Table 26 - Study model and serology results
1 mean titres + ELISA IBD, expressed as log 10 in the serum of 5 animals per sampled group at D23 before challenge; 2The bursal weight / body weight of the unvaccinated / unchallenged group was 0.0047
[0214] The mean ELISA + IBD serological titer was 4.36 ± 0.01 log 10 indicating a very high level of maternal IBD antibodies in the offspring. At D23, the mean ELISA + IBD titer was still high (3.9) in the Gl control. The mean ELISA titers of the vaccinated groups were not significantly different from those of the control group.
[0215] Neither morbidity nor mortality was observed in any of the groups after challenge. Percentages of protection against severe bursal injuries are shown in table 26 above. The result showed that co-administration of vHVTl14, VSB1-007 or VSB1-009 VSB did not interfere with vHVT13 induced by IBD protection indicating a lack of interference. Likewise, the mean bursal/body weight ratios of the vaccinated groups were similar and clearly superior to that of the control group, indicating IBD protection and there was no difference between vaccination regimens.
[0216] In conclusion, the data indicates the compatibility between vHVTl14, vSBl-007 or VSB 1-009 and vHVT13 for IBD protection. The absence of interference between the two HVT vectors for IBD protection was again surprising and confirmed the results observed for ND protection (see example 10), Example 15 The efficacy of dual HVT + IBD-ND (vHVT304 and vHVT306) associated or not with SB-1 and of SB1-ND (vSBl-007 and vSBl-008) in combination with vHVT13 recombinant vaccines, against challenge with a variant And IBDV isolate at D28 in SPF chickens
[0217] The aim of the study was to evaluate the efficacy of two dual HVT vaccine vectors (HVT + IBD-ND: vHVT304 and vHVT306) or two VSB-l-NDV in combination with vHVT13 (vSBl-007 + vHVT13, vSBl-008 + vHVT13) administered subcutaneously (SC) to SPF birds for days of age, and challenged with IBDV variant (VAR-E) at 28 days post-vaccination.
[0218] At DO, 105 one-day-old SPF birds were randomly assigned to 7 groups of 15 birds, including a group of challenged controls (G6) and unchallenged controls (G7). Birds from group G1 to G5 were injected subcutaneously into the neck at the OD with 0.2 ml of recombinant vaccines and/or CGS-1 each containing a target dose of 2000 pfu. The study design is shown in Table 27 below. On D28, all birds from groups G1 to G6 were challenged with eye drops (0.03 mL containing 3 log 10 EID50 per bird) of IBDV E variant isolated from the University of Delaware (USA). Each group was monitored before and after the challenge. Eleven days after the challenge, the birds were weighed and necropsied. The bag was collected and weighed. Bursal/body weight ratios (bursal weight/body weight ratio x 100) were calculated. Table 27 - Study design and IBD efficacy results

[0219] The mean bursal/body weight ratios are shown in Table 27. The challenged control birds had severe bursal atrophy compared to the unchallenged ones. VSB 1-007 and VSB1-008 VSB vaccines did not interfere with vHVT13 protection induced by (G4 and G5). Bursal/body weight ratios of birds vaccinated with the dual HVT (HVT + IBD-ND) were slightly lower than the unchallenged control group, but were clearly higher than the challenged control groups. Furthermore, serotype 2 of the SB-1 vaccine against Marek's disease did not interfere with the protection induced by vHVT304 IBD.
[0220] In conclusion, these data indicate that the combination of an SB1-ND vector with a single HVT-IBD or double HVT expressing NDV-F and -IBDV VP2 induced IBD protection in an IBDV E variant challenge model. Example 16 - Lack of interference from vHVT114, vSBl-009 and/or SB-1 in the vHVT13 variant induced protection in the E variant of IBD in SPF chickens.
[0221] The aim of the study was to evaluate the IBD efficacy of vHVT13 when administered via the SC route or in ovo concurrently with vHVTl14, VSB 1-009 and/or SB-1 in SPF birds in an IBDV (VAR-E) variant in the model of challenge in D28.
[0222] 75 one-day-old SPF birds and 75 18 to 19-day-old SPF chicken embryo were randomly allocated into 5 groups (GL to G5 and G6 to G10, respectively), including a group of challenged controls (G4 and G9, respectively) and unchallenged controls (G5 and G10, respectively). Birds from the GL to G3 groups were injected subcutaneously in the neck in the DO with 0.2 ml of vaccines each containing a target dose of 3,000 pfu except for SB-1, which had a target dose of 1,000 PFU. Birds from G6 to G8 received the same doses of vaccine, but in 0.05 mL volume by in ovo route 2-3 days before litter. The study design is shown in Table 28 below. At 28 days of age, all birds from groups G1 to G4 and G6 to G9 were challenged with drops (0.03 mL containing 3 log 10 EID50 per bird) of IBDV variant E isolated from the University of Delaware (USA). Each group was monitored before and after the challenge. Eleven days after the challenge, birds were weighed and necropsied. The bag was collected and weighed. Bursal/body weight ratios (bursal weight/body weight ratio x 100) were calculated. Table 28 - Study design and IBD efficacy results

[0223] The mean bursal/body weight ratios are shown in Table 28. The challenged control birds (G4 and G9) had severe bursal atrophy compared to the unchallenged ones. The bursal/body weight ratios of the vaccinated groups (G1 to G3 and G6 to G8) were similar to those of the unchallenged control groups (G5 and G10) and well above the challenged control groups (G4 and G9). The lack of interference of vHVT114 in vHVT13 induced IBD protection after either the SC or in ovo pathway was surprising and the data obtained in examples 10 and 14 confirmed.
[0224] In conclusion, these data clearly indicate the compatibility of vHVTl14 + VSB 1-009 or + SB-1 and VSB 1009 with vHVT13 when administered by SC route or in ovo in an IBDV variant E challenge model. Example 17 - Efficacy of vHVT114 and vHVT13 and SB1 or vSBl-009 vectors against much more virulent challenge in Marek's disease
[0225] The aim of this study was to evaluate the efficacy of Marek's disease induced by different combinations of vaccines, including vHVTl 14, vHVT13, SB-1 and/or VSB 1-009 administered via SC to day-old SPF birds and challenged four days later with the much more virulent Marek's disease virus isolate T-King (w + MDV).
[0226] At DO, 100 one-day-old SPF birds were randomly assigned to 5 groups of 20 birds. Birds in group 1 to 3 were injected subcutaneously in the neck at the OD with 0.2 mL of vaccines containing a target dose of 2000 pfu for each vaccine, except for SB-1, for which the target dose was 1000 pfu. Birds from groups 4 and 5 were unvaccinated and were used as challenged (group 4) or non-challenged (group 5). The study model is shown in Table 29. On D4, all birds from groups 1 to 4 were inoculated with 0.2 ml of the MDV w + isolate T-King using the intraperitoneal route of administration. Table 29 - Study model and MD protection results


[0227] Each group was monitored daily for any adverse reactions, before and after challenge. On day 49, all live birds were sacrificed and necropsied to examine for macroscopic lesions associated with Marek's disease. Chickens were classified as positive for infection with Marek's disease if nervous signs such as paralysis, locomotive signs attributable to the disease, and severe weight loss or depression are observed, if mortality directly attributable to Marek's disease occurs, or if macroscopic lesions are observed at necropsy. Injuries may include, but are not limited to, the following: liver, heart, spleen, gonad, kidney and muscle damage.
[0228] Protection results are shown in Table 29 above. All vaccinated groups (G1 to G3) performed equally, inducing partial protection (65%) MD as expected in this very severe and early challenge model. These results indicated that vector vaccines retain their ability to protect against Marek's disease. Example 18 - Efficacy of recombinant HVT and SB1 vectors against Marek's Disease
[0229] The efficacy of Marek's disease is also demonstrated for recombinant HVT and SB-1 vectors, either alone or in combination. Challenge strains include a virulent Marek's disease (VMD) challenge such as GA22, a highly virulent Marek's disease (ADM) challenge such as RB1B, and/or a much more virulent Marek's disease (w + MD) challenge such as the T.King virus. One day old birds are inoculated subcutaneously or 18 - 19 days old, embryonated eggs are inoculated with a dose of 0.2 ml or 0.05 ml dose, respectively, of the test virus. At five days of age, vaccinated birds and native controls are challenged with relevant Marek's virus challenge (v, w, w + or MDV). Challenged birds are observed up to seven weeks of age. All birds are sacrificed and necropsied to observe grossly visible lesions associated with Marek's disease, as described in Example 17. Example 19 - Interference of HVT IBDV on vHVT13-induced antibodies in commercial chickens
[0230] The aim of this study was to determine whether co-administration of HVT with vHVT13 had an impact on vHVT 13 induced by IBDV antibody response in commercial chickens.
[0231] Eighty day-old commercial chickens were used in three isolation units. Fifteen blood were collected at one day of age to test maternal IBD antibodies (MDA). The remaining birds were divided into three groups as shown in Table 30. Birds in groups 2 and 3 were vaccinated SC in the nape of the neck with commercial doses of vHVT13. (Vaxxitek HVT + IBD; Merial SAS, Lyon, France) and/or HVT Bio HVT (Merial SpA, Noventa, Italy) associated with the cell. Blood samples were taken at the age of 25, 35 and 45 days of age. The ELISA kit to assess the IBDV serological response was the PROFLOK PLUS IBD (DII+) Symbiotic Ab ELISA kit (Symbiotics Corp, Kansas City, MO, USA). Table 30 - Study model and serology results

[0232] mean ELISA titers are shown in Table 30. Titers in the unvaccinated group G1 decreased from D1 to D45, which corresponded to the decline in maternal IBD V antibodies. As expected; ELISA titers in the G2 vHVT13 group remained elevated until D45 indicating maternal antibodies were progressively replaced by induced vHVT 13 antibodies. The addition of HVT to vHVT13 had a clear negative impact since the antibody titers observed in G3 were similar to G1. These results contrast with those obtained with vHVTl 14 + vHVT13 since vHVTl 14 did not decrease ELISA induced vHVT13 + IBD titers (see Example 14, Table 26). They confirm the unexpected property of vHVT114 in not interfering with vHVT13 immunogenicity.
[0233] In conclusion, contrary to what was seen with vHVTl14, the addition of HVT to vHVT13 had a clear negative impact on vHVT 13 induced by humoral IBDV immunity. Example 20 - Interference of commercial HVT-ND or vHVT13 induced by IBD protection
[0234] The aim of this study was to determine whether co-administration of commercial HVT-ND vector vaccines with vHVT13 had an impact on vHVT 13 induced by IBD protection in SPF chickens.
[0235] Seventy-five SPF chickens (3 groups (G2, G3 and G4) of 25) were vaccinated at one day of age, via SC with a commercial dose of vHVT13 (Vaxxitek HVT + IBD), with or without one commercial ND-HVT licensed vector vaccine dose (vHVT-NDL and vHVT-ND2) as shown in Table 31. Fifteen birds were maintained as unvaccinated controls (Gl). Three weeks after vaccination, birds (20 chickens in G2, G3 and G4 and 10 chickens in Gl) were challenged with at least 2.0 log 10 DIO50 in 0.05 ml of IBD Ph / Bl virus strain (isolated in the Philippines), administered by the ocular route. All chickens were observed for 5 days for clinical signs or death from causes attributable to IBD virus challenges and humanely euthanized at the end of post-challenge observation for necropsy examination of IBD lesion, especially from Fabrício's bag . Birds were considered protected if their bursa did not show bursal lesions typical of IBD: bursal atrophy, peri-bursa edema and/or hemorrhages in bursa tissues. Table 31 - IBD Study Model and Data Protection

[0236] Results are shown in Table 31. All 10 challenged control birds showed clinical signs and 8 of 10 died 4 or 5 dpi indicating that the IBDV challenge was very severe. All of them had severe bursa lesions, including severe atrophy and hemorrhagic spots. vHVT13 alone induced full protection whereas both combinations with vHVT-ND induced clinical and partial bursal protection.
[0237] In conclusion, these results clearly indicate that the two commercial ND-vectored HVT vaccines interfere with vHVT13 induced by IBD protection. Example 21 - Efficacy of vSB1-004, vSB1-006, vSB1-007, vSB1-008, ND SB1-vectored vaccines alone or in association with the vectorized vaccine IBD-HVT vHVT13, and the vaccines vHVT302 and vHVT304 against challenges with the NDV strain Texas GB at 14 and/or 28 days of age in SPF chickens.
[0238] The aim of the study was to evaluate the effectiveness of combinations of different Marek's Disease vector vaccines expressing the NDV F and/or the IBDV VP2 gene against Newcastle disease challenge (Texas GB strain, genotype II) performed at 14 and/or 28 days of age in SPF chickens.
[0239] The characteristics of the 6 NDV recombinant vaccines tested in this study are described in Table 32 below. Table 32 - Characteristics of the 6 NDV recombinant vaccines tested in this study

[0240] At DO, 225 one-day-old SPF chickens were randomly assigned to 9 groups of 15 birds (G1a to G9a challenged to D14) and 6 groups of 15 birds (G1b, G3b, G4b, G5b, G8b, G9b challenged to D28). Birds were injected subcutaneously in the neck in the DO with 0.2 ml containing a target dose of 2000 pfu for recombinant vaccines. The study model is shown in Table 33 below. Birds were challenged intramuscularly on D14 or D28 with 4.3 and 4.2 log 10 DIO50 (0.1 mL) velogenic strain ND Texas GB (genotype II), respectively. Table 33 - Results of ND Efficacy

[0241] Each group was monitored before and after the challenge. NDV clinical signs were recorded after challenge. One bird died in G6 and G7 before the challenge of reducing the number of birds 15 - 14 in these groups.
[0242] Percentages of clinical protection (including protection from mortality and morbidity) are presented in Table 33 above. Complete susceptibility was observed in the unvaccinated Gla and G1b challenged control group, thus validating the high severity of the challenge. Partial protections ranging from 13.3 - 46.6% were observed after challenge at D14, the highest levels of protection being induced by vSBl-008, vSBl-007 and vHVT304. Protection levels after the ND challenge at D28 were much higher for all vaccinated groups and were again slightly higher in the groups vaccinated with vSB1-008, VSB 1-007 or vHVT304. These results indicate that protection levels were ND dependent on challenge date and construct. Constructs VSB1-008 and VSB 1-007 performed slightly better than VSB1-004 and VSB1-006, and vHVT304 performed slightly better than vHVT302, indicating that different characteristics of the constructs are playing a role in the performances of vector-based vaccines. MDV.
[0243] In conclusion, the results of this study showed that the levels of ND protection induced by Marek's disease vectors expressing NDV F genes may depend on different parameters, including the vector, the insertion site, the F gene, the promoter, the polyadenylation site and the challenge conditions. Example 22 - Efficacy of dual HVT + IBD-ND vHVT304 and vHVT306 vaccines against challenges with NDV Texas GB strains at 14 and/or 28 days of age in SPF chickens
[0244] The aim of the study was to evaluate the efficacy of the HVT-vector vaccine expressing NDV F and VP2 IBD V genes against the challenge of Newcastle disease (Texas GB strain, genotype II) performed at 14 and/or 28 days of age in SPF chickens.
[0245] The characteristics of the two recombinant vaccines tested in this study are described in Table 34 below. Table 34 - Characteristics of the recombinant vaccine candidates used in this study

[0246] At DO, 90 one-day-old SPF chickens were randomly assigned to 3 groups of 15 birds (G1a to G3a challenged on D14) and 3 groups of 15 birds (G1b to G3b challenged on D28). Birds were injected subcutaneously in the neck in the DO with 0.2 ml containing a target dose of 2000 pfu for recombinant vaccines. The study design is shown in Table 35 below. Birds were challenged intramuscularly on D14 or D28 with a target dose of 4.0 log 10 DIO50 (0.1 mL) of ND Texas GB velogenic strain (Genotype II). Table 35 - Results of ND Efficacy

[0247] Each group was monitored before and after the challenge. NDV clinical signs were recorded after challenge. One bird died in G2b before the challenge with a reduction in the number of birds 15 - 14 in this group.
[0248] Percentages of clinical protection (including protection from mortality and morbidity) are presented in Table 35 above. Complete susceptibility was observed in the unvaccinated Gla and G1b challenged control group, thus validating the high severity of the challenge. Protections levels after the challenge at D14 were much lower than those obtained after the challenge at D28. These candidate vaccines had the same NDV F expression cassette inserted at 2 different loci of the vHVT13 genome. They performed equally in terms of ND protection under the conditions tested, indicating that both insertion loci (IG2 and SORF3-US2) are equally suitable for insertion of the NDV F cassette.
[0249] In conclusion, the results of this study showed that the levels of ND protection induced by Marek's disease vectors expressing NDV F genes depend on several parameters, such as the vector, the insertion site, the F gene, the promoter , the polyadenylation site and the challenge conditions. Example 23 - Early ND efficacy induced by the pair of HVT-ND + IBD vectors (vHVT302, VHVT303 and vHVT304) or SB-1 vectors (vSBl-006 and vSBl-007) at one day of age in SPF broilers against a genotype velogenic challenge V NDV.
[0250] The aim of the study was to evaluate the efficacy of three pairs HVT + IBD-ND (vHVT302, vHVT303 and vHVT304) and two SB1-ND vectors (vSBl-006 and VSB 1-007) at one day of age in SPF chickens against a genotype V (Chimalhuacan) NDV velogenic challenge performed on D14.
[0251] The characteristics of the five recombinant vaccine candidates tested in this study are described in Table 36 below. Table 36- Characteristics of the recombinant vaccine candidates used in this study

[0252] Six groups (1 and 2) of 10 one-day-old white Leghorn Chicks specific pathogen free (SPF) were randomly constituted. Birds from groups 2 to 6 were vaccinated subcutaneously (the nape of the neck) with a target dose of 2000 PFU as shown in Table 37 below. Group 1 chickens were not vaccinated and were kept as control birds. At two weeks of age, all birds were challenged with the velogenic V genotype of the Mexican Chimalhuacan (Mex V) NDV strain. The challenge was performed intramuscularly (IM) by means of 105 Egg of the infective dose 50 (EID50) diluted in 0.2 ml of physiological sterile water. All birds were monitored up to 14 days after challenge. After the challenge, the health status of each bird was marked daily as follows: healthy / with specific symptoms (ruffled feathers, prostration, stiff neck, tremor) / dead. Any bird that showed specific symptoms for more than 2 days or sick was observed on D28 was taken into account for the calculation of morbidity. Table 37 - Results of early ND protection induced by different MDV vector candidates expressing NDV F gene in day-old SPF birds

[0253] Protection results are summarized in Table 37. All control birds died after the ND challenge. Variable levels of ND protection were induced by the different vaccines tested ranging from 10% to 80% and between 0% and 60%, in terms of protection against mortality and morbidity, respectively. Candidate vHVT304 induced better protection than candidates vHVT303 and vHVT302; this could be due to the exogenous SV40 promoter placed in front of the NDV F gene. The VSB 1-007 performed slightly better than the VSB 1-006. Furthermore, the performances obtained with vHVT304 were comparable to those obtained with VSB1-007 indicating that different vectors of Marek's diseases can achieve the same level of ND protection.
[0254] In conclusion, this study demonstrates that both the SB1-ND vectored vaccine and the dual HVT + IBD-ND vaccine can achieve significant levels of ND protection in a very severe and early NDV challenge model. Example 24 - Efficacy ND induced by double HVT-ND + IBD vHVT306 administered via in ovo or SC at one day of age, against SPF chickens with a V NDV velogenic genotype challenge performed at D28
[0255] The aim of the study was to evaluate the efficacy of a dual HVT + IBD-ND (vHVT306) administered via in ovo or SC to SPF broilers against a genotype V (Chimalhuacan) NDV velogenic challenge performed at 28 days of age.
[0256] The characteristics of the recombinant vaccine candidate vHVT306 tested in this study are described in Table 38 below. The single HVT-IBD vHVT13 vector vaccine was used as a control. Table 38 Characteristics of the candidate recombinant vaccine used in this study

[0257] On day 3, 40 SPF embryonated eggs aged around 18 days and 18 hours of incubation were randomly allocated into two groups of 20 eggs each. In DO, a group of 12-day-old SPF chicks was added. The definition of groups is presented in Table 39 below. Vaccination was performed at D-3 (via in ovo) or at OD (via SC, at the back of the neck) and the target dose of vHVT306 and vHVT13 was 2000PFU/bird. For the egg route, hatchability, viability (until D28) and bird growth (between hatch and D28) were monitored.
[0258] On D28, 10 birds per group were challenged with the virulent ND Chimalhuacan strain. The challenge was performed intramuscularly (IM) using 105 Egg of the Infectious Dose 50 (EID50) diluted in 0.2 ml of sterile physiological water. Birds were monitored up to 14 days after challenge. Specific clinical signs and mortality were recorded. Any bird that showed specific symptoms for more than 2 days or sick was observed in D42 taken into account for the calculation of morbidity. Five and seven days after the challenge (ie, on D33 and D35), oropharyngeal swabs were taken from each surviving bird. All swabs were analyzed by specific qRT-PCR NDV. ND vHVT306 MDV-induced protection results from candidate vectored MDV expressing NDV F and IBDV VP2 genes administered by SC route or in ovo in SPF chicks
G3 vHVT306/SC - 100% / 100% 20% (3.2) / 10% (2.9) * The threshold titer of the real-time RT PCR was 2.7 log 10 DIO50 equivalent
[0259] Total hatchability was recorded after in ovo vaccination in groups 1 and 2 and all hatched birds survived until D28. There was no difference in body weight that was detected between the two groups for either D28 confirming the perfect safety of vHVT306 when administered in ovo. Protection results are summarized in Table 39. All vHVT13 vaccinated control birds died by 4 days after the ND challenge. Complete clinical ND protection was induced by vHVT306 administered by both routes. Furthermore, no protection was detected after in ovo administration. Whereas only a few birds alter the detectable amount of virus challenge after SC administration.
[0260] In conclusion, this study demonstrates that dual HVT + IBD-ND vHVT306 induced excellent level of ND protection by SC or in ovo administration routes in a very severe heterologous NDV challenge model. Example 25 - Efficacy of dual IBD recombinant vaccines (vHVT302, vHVT303 and vHVT304) against challenge with a classic IBDV HVT-ND + isolated at D15 in SPF chickens.
[0261] The aim of the study was to evaluate the early efficacy of IBD of dual recombinant HVT constructs vHVT302, vHVT303 and vHVT304 against a challenge of virulent bursal infectious disease virus (vIBDV) (Faragher 52/70 strain), performed at 15 days of age in SPF chickens.
[0262] The characteristics of 3 dual recombinant HVT-ND + IBD candidate vaccines tested in this study are described in Table 40 below. Table 40 - Characteristics of double recombinant HVT expression cassettes

[0263] At DO, 40 one-day-old SPF chickens were randomly assigned to 4 groups of 10 birds, including a control group (OG), which was vaccinated with VSB 1-004, an SB-1 vector expressing NDV F gene Five other SPF birds were kept unvaccinated and challenged for bursal/body weight assessment. Birds were injected by subcutaneous injection into the neck at the OD with 0.2 ml of the recombinant vaccines containing a target dose of 2000 pfu, as described in Table 41 below. At D15, a blood sample was collected from all birds per group (10 birds per group, except for groups 1 and 3 where one bird died before blood sampling) for serological testing with the ProFLOK ® plus IBD Kit (Symbiotic Corp). On D15, birds from all 4 groups were challenged with eye drops (0.05 mL per bird) with 2.5 loglo DIO50. Table 41 - Study design and IBD efficacy results
Birds sick for more than 2 days or still sick on D25 were considered as sick. The number in parentheses is the total number of birds in the group that were challenged. 2Protection against clinical signs and severe bursal lesion (bursal score <3) 4The bursal weight/body weight ratio of the unvaccinated/unchallenged group was 0.0043.
[0264] Each group was monitored before and after the challenge. Clinical signs of IBDV were recorded for one day after challenge (from D15 to D25). At the end of the post-challenge observation period (D25), all surviving birds were sacrificed and autopsied. Body and bursal weights were recorded. Each Fabricio bag (BF) was weighted then stored in individual containers containing 4% formaldehyde for histology. Histological bursa lesions were scored according to the scale shown in Table 42. Table 42 - Fabricius bursa histological lesions scoring scale*


[0265] A bird was considered to be affected if it died and/or demonstrated notable signs of disease and/or severe lesions of the bursa of Fabricius (ie, histology score >3).
[0266] Significant ELISA antibody titre DII+ expressed in log 10 before challenge is shown in Table 41. Significant titres were detected in all vaccinated groups that were significantly higher than that of the control group G1. serology was slightly higher in G3 (vHVT303).
[0267] Severe clinical signs were observed after challenge in all 9 birds in the Gl control group, which led to the death of one bird. Only one bird vaccinated in G2 (vHVT302) showed clinical signs after challenge. Percentages of protection against severe bursal injuries are shown in Table 41 above. Significant IBD protection was observed in all vaccinated groups, full protection being seen in G3 (vHVT303). Mean bursal/body weight indices are also shown in Table 41. Indices in all vaccinated groups were higher than in the Gl-challenged control group and not significantly different from the unvaccinated and unchallenged control group.
[0268] In conclusion, these data indicate that the three pairs HVT-DII + ND tested in this study of antibody induced IBD and early protection DII in a challenge model of severe IBDV. Example 26 - The efficacy of five different HVT-ND vaccine candidates against challenges with velogenic NDV ZJL (Vlld genotype) isolated at 14 days of age in SPF chickens.
[0269] The aim of the study was to evaluate the efficacy of 5 individual recombinant HVT constructs (vHVT39, vHVTl10, vHVTl11, vHVTl12 and vHVTl13) that express the NDV F gene against the challenge of Newcastle disease with velogenic NDV ZJ1 (Vlld genotype) isolated performed at 14 days of age in SPF chickens.
[0270] The characteristics of these five vaccine candidates are described in Table 43 below. Table 43 - Characteristics of the HVT-ND recombinant viruses used in the challenge study.
* Wt means that the wild type velogenic F gene sequence was used, but the cleavage site was modified to that of a lentegenic virus. Wtnm means that the wild-type sequence cleavage site has not been modified. The Texas velogenic strain belongs to genotype IV and YZCQ to genotype Vlld.
[0271] At DO, 72 one-day-old SPF birds were randomly assigned to 5 groups of 12 birds (vaccinated) and one group of 12 birds (unvaccinated controls). Birds were injected subcutaneously into the neck at the OD with 0.2 ml of the recombinant vaccines, containing a target dose of 6,000 pfu, as described in Table 44 below. Birds were challenged intramuscularly on D14 with 5 log 10 EID50 of velogenic strain NDV ZJ1/2000 (Vlld genotype). Table 44 - Results of ND Efficacy

[0272] Each group was monitored before and after the challenge. NDV clinical signs and mortality were recorded after challenge. Oropharyngeals were taken 2 to 4 days post-infection (dpi) for the assessment of viral load by real-time RT-PCR, using the method described by Wise et al. (2004; Development of a Real-Time Reverse-Transcription PCR for Detection of Newcastle Disease Virus RNA in Clinical Samples. J Clin Microbiol 42, 329-338).
[0273] Percentages of protection from mortality and morbidity are reported in table 44 above. Complete susceptibility was observed in the unvaccinated G1 challenged control group, thus validating the high severity of the challenge. Vaccines induced variable levels of protection against mortality (25 - 100%) or against morbidity (8% - 83%). The best level of protection was induced by vHVTl10, while the lowest was induced by vHVT039, the other candidates giving intermediate results. Oropharyngeal protection results at 2 and 4 dpi are also presented in Table 44 above and are in line with those for clinical protection. These vaccine candidates differ in their promoter and F gene sequence. These results show that the two parameters are important for designing the ideal HVT-ND vaccine candidate.
[0274] In conclusion, the results of this study show the importance of the promoter and the F gene sequence in the ND efficacy induced by HVT-vectored ND vaccine candidates. Example 27 - Evaluation of the efficacy of Newcastle disease induced by double SB1 constructs expressing IBDV VP2 and NDV F.
[0275] The aim of the study is to assess the efficacy of SB1 dual constructs expressing IBDV VP2 and NDV F against the challenge of Newcastle disease.
[0276] In DO, one-day-old SPF chickens are randomly assigned to several groups of 10 - 20 birds, including the vaccinated and unvaccinated groups. Birds from the vaccinated groups were injected subcutaneously into the neck at the OD with 0.2 ml containing a target dose of 1000 pfu and 5000 pfu recombinant vaccines. Alternatively, the same 0.05 ml dose can be administered in ovo within 2 or 3 days before hatching. Birds (at least one vaccinated group and one unvaccinated group) are challenged intramuscularly at different time after vaccination: eg D14, D28 or D42 with about 4.0 log 10 DIO50 (0.1 mL ) from a velogenic strain NDV strain such as Texas GB (genotype II), ZJ1 (genotype Vlld), Chimalhuacan (genotype V).
[0277] Each group is clinically followed before and after the challenge. NDV clinical signs (morbidity) and mortality are recorded after challenge. Clinical protection percentages across all groups are calculated. At least 90% of unvaccinated SPF challenged birds must die or become seriously ill after challenge to validate the severity of challenge. Oropharyngeal and cloacal samples can be taken at different times after challenge, such as 3, 5, 7 and 9 days after challenge and viral load can be estimated by real-time RT-PCR. The best candidates will be those that induced the highest level of clinical protection and lowest level of viral load in the swabs. A similar study can be performed in chickens containing maternal NDV antibodies; however, these maternal antibodies could potentially protect unvaccinated birds if challenged early. The SB1 dual construct can also be tested in combination with Marek's disease vaccine or other vector vaccines. Example 28 - Evaluation of the efficacy of infectious bursal disease induced by SB1 double construct expressing IBDV VP2 and NDV F.
[0278] The aim of the study is to assess the IBD efficacy of the SB1 dual construct expressing both the IBDV VP2 and the NDV F.
[0279] One-day-old SPF chickens are randomly allocated to various groups of 10 to 20 birds, including vaccinated and unvaccinated controls. Unvaccinated controls will be separated into two subgroups, including challenged and unchallenged birds. Birds from vaccinated groups were injected subcutaneously into the neck at the OD with 0.2 ml of vaccines each containing a target dose of 1000 and 5000 pfu. Alternatively, the same 0.05 ml dose can be administered in ovo within 2 or 3 days before hatching. At different times after vaccination, such as 14, 21, 28 or 42 days post-vaccination, all birds in the vaccinated groups and challenged controls are challenged with eye drops (0.03 mL containing 2 to 4 log 10 EID50 per bird) from a virulent IBDV (such as the Faragher strain or the US standard strain), a highly virulent VDBI such as the 91 - 168 isolate, or an isolated variant IBDV such as the E Delawerw US variant isolate. Each group is clinically monitored before and after the challenge. Birds can be necropsied 4 or 5 days post-challenge to assess macroscopic bursal lesions. They can also be necropsied 10 to 11 days after challenge. Macroscopic and/or histological lesions can be evaluated. In addition, birds and bursa are weighed the bursal/body weight, proportions (bursa/body weight ratio x 100) is calculated in relation to those of the unvaccinated challenged group. SPF-challenged control birds must show clinical signs and/or have significant gross values and/or histological lesions and/or must have a significantly lower bursal/body weight ratio than non-vaccinated unchallenged control birds to validate the severity of challenge. Vaccine efficacy is assessed by comparing these parameters with unvaccinated/challenged groups and unvaccinated/unchallenged groups. Such a study can be carried out in broiler chickens containing maternal IBDV antibodies; however, these maternal antibodies could potentially protect unvaccinated birds if challenged early. The SB1 dual construct can also be tested in combination with Marek's disease vaccine or other vector vaccines. Example 29 - Evaluation of the efficacy of Marek's disease induced by SB1 dual constructs expressing IBDV VP2 and NDV F.
[0280] The aim of this study is to assess the efficacy of Marek's disease induced by SB1 vectors that express both IBDV VP2 and NDVF.
[0281] One-day-old SPF chickens are randomly assigned to various groups of 20 to 50 birds, including vaccinated and unvaccinated controls. Unvaccinated controls can be separated into two subgroups, including challenged and unchallenged birds. Birds from vaccinated groups were injected subcutaneously into the neck at the OD with 0.2 ml of vaccines each containing a target dose of 1,000 and the 5000 pfu. Alternatively, the same 0.05 ml dose can be administered in ovo within 2 or 3 days before hatching. At different times after vaccination, such as 3 to 10 days after vaccination, all birds in the vaccinated groups and challenged controls are challenged intraperitoneally with 0.2 ml of the Marek's disease virus strain one (MDV). MDV strain can be of various pathotypes such as virulent MDV (vMDV), including the isolated JM or GA22, very virulent MDV (wMDV) such as the RB-1B or MD5 isolates, much more virulent (+ w MDV), such as the T- isolates. King or 648A. Challenge with the MDV strain inoculum are prepared by infecting chickens, harvesting and freezing their blood cells in liquid nitrogen in the presence of a cryopreservative such as DMSO. The chicken infectious dose 50 (CID50) is established for each batch of challenge before conducting vaccination/challenge studies. Each group is clinically monitored before and after the challenge. Birds are autopsied at least 7 weeks after vaccination and the presence of macroscopic Marek's disease lesions is checked in each bird. Injuries may include, but are not limited to, the following: liver, heart, spleen, gonad, kidney, nerve and muscle damage. Such a study can be performed in broiler chickens containing maternal MDV antibodies. The dual SB1 construct can also be tested in combination with other Marek's disease vaccines (eg HVT and or CVI988 Rispens strains) or MD vector vaccines. The MD Challenge can also be performed by contact between vaccinated birds and non-vaccinated SPF MDV infected birds.
[0282] Having thus described in detail the preferred embodiments of the present invention, it is to be understood that the invention defined by the above examples is not to be limited to the specific details defined in the above description as many obvious variations thereof are possible without departing of the spirit or scope of the present invention.
[0283] All documents cited or referenced in this report ("documents referenced herein"), and all documents cited or referenced herein are cited documents, along with any manufacturer's instructions, descriptions, product specifications, and product sheets of all products herein or in any document incorporated by reference mentioned herein, are incorporated herein by reference, and may be employed in the practice of the invention.

权利要求:
Claims (10)
[0001]
1. Composition or vaccine characterized in that it comprises: a first vector of recombinant turkey herpesvirus (HVT) that comprises a heterologous polynucleotide that encodes and expresses a Newcastle Disease Virus (NDV-F) antigen operably linked to a SV40 promoter and an SV40 polyA signal, wherein the polynucleotide encoding the NDV-F polypeptide, the operably linked SV40 promoter, and the SV40 polyA signal are further inserted into the intergenic region 1 (IG1) of the genome locus of HVT, wherein the polynucleotide encoding and expressing NDV-F has the sequence defined in SEQ ID NO: 1, wherein the SV40 poly A signal has a sequence as set forth in SEQ ID NO: 11 or 12, and the SV40 promoter has a sequence as set forth in SEQ ID NO: 10; and a second recombinant HVT vector comprising a heterologous polynucleotide encoding and expressing a Gumboro Disease Virus (IBDV) VP2 antigen, wherein the second recombinant HTV vector is vHVT13, wherein the VP2 antigen has a conforming sequence set forth in SEQ ID NO: 7.
[0002]
2. Composition or vaccine, according to claim 1, characterized in that the composition further comprises one or more SB1 recombinant vectors, wherein the SB1 vector is selected from the group consisting of vSB1-009 comprising an SV40 promoter and a codon optimized polynucleotide encoding an NDV-F antigen of the CAOQ2 genotype inserted into the UL44 locus of the SB1 genome; vSB1-010 comprising a guinea pig CMV promoter and a polynucleotide encoding an NDV-F antigen of genotype VIId inserted into the SORF4-US2 locus of the SB1 genome; vSB1-004 comprising an mCMV IE promoter and a polynucleotide encoding an NDV-F antigen of genotype VIId inserted into the US10 locus of the SB1 genome; vSB1-006 comprising an SV40 promoter and a codon optimized polynucleotide encoding an NDV-F antigen of genotype VIId inserted into the UL55/LORF5 locus of the SB1 genome; vSB1-007 comprising an SV40 promoter and a codon optimized polynucleotide encoding an NDV-F antigen of the VIId genotype inserted into the UL44 locus of the SB1 genome, and vSB1-008 comprising an SV40 promoter and a codon optimized polynucleotide encoding an NDV antigen -F of the CA02 genotype inserted into the UL55/LORF5 locus of the SB1 genome, where the SV40 promoter has a sequence as set forth in SEQ ID NO: 9, the codon optimized polynucleotide encoding an NDV-F antigen of the CAOQ2 genotype has a sequence as set forth in SEQ ID NO:5, the guinea pig CMV promoter has a sequence as set forth in SEQ ID NO:43, the polynucleotide encoding an NDV-F antigen of genotype VIId has a sequence as set forth in SEQ ID NO:3, the mCMV IE promoter has a sequence as set forth at nucleotides 1241 to 2661 of SEQ ID NO: 29 and the codon optimized polynucleotide encoding an NDV-F antigen of genotype VIId has a sequence as set forth. given in SEQ ID NO: 1.
[0003]
3. Composition or vaccine, according to claim 1, characterized in that the first recombinant HVT vector comprises a sequence as set forth in SEQ ID NO: 18.
[0004]
4. Composition or vaccine, according to claim 2, characterized in that the SB1 vector comprises a sequence as set out in SEQ ID NO: 19 or SEQ ID NO: 40.
[0005]
5. Use of the composition or vaccine as defined by any one of claims 1 to 4 characterized in that it is for the preparation of a drug for the vaccination of an animal.
[0006]
6. Use of the composition or vaccine as defined by any one of claims 1 to 4 characterized in that it is for the preparation of a drug to induce an immunogenic or protective response in an animal against Newcastle Disease Virus (NDV), or Infectious Bursal Disease Virus (ie IBDV or Gumboro Disease Virus) and Marek's Disease Virus (MDV).
[0007]
7. Use according to claim 5 or 6, characterized in that the animal is a bird.
[0008]
8. Use according to claim 7, characterized in that the bird is a chicken, duck, goose, turkey, quail, pheasant, parrot, finch, falcon, raven, ostrich, rhea or cassowary.
[0009]
9. Use according to claim 8, characterized in that the bird is a chicken, duck, goose, turkey, quail, pheasant, ostrich, rhea or cassowary
[0010]
10. Use according to claim 9, characterized in that the bird is a chicken, duck, goose, turkey, quail or pheasant.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112014013276B1|2021-07-27|RECOMBINANT HVT VECTORS EXPRESSING AVIAN PATHOGEN ANTIGENS AND USES THEREOF

---

US9555096B2|2017-01-31|Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof

---

RU2752836C2|2021-08-09|Recombinant hvt-vectors expressing multiple antigens of avian pathogens and vaccines containing these vectors

---

US9770502B2|2017-09-26|Recombinant gallid herpesvirus 3 | vectors expressing antigens of avian pathogens and uses thereof

---

US11090377B2|2021-08-17|Avian reovirus vaccines

---

US20200323978A1|2020-10-15|Recombinant non-pathogenic marek&#39;s disease virus constructs encoding multiple heterologous antigens

同族专利:

---

公开号 | 公开日

---

ES2775218T3|2020-07-24|

---

AR090401A1|2014-11-12|

---

DK2785373T3|2020-02-03|

---

SI2785373T1|2020-02-28|

---

MX365984B|2019-06-21|

---

KR20140097515A|2014-08-06|

---

HK1248566A1|2018-10-19|

---

UA118651C2|2019-02-25|

---

HRP20192241T1|2020-03-06|

---

HUE042471T2|2019-07-29|

---

CY1121528T1|2020-05-29|

---

PH12015502790B1|2017-07-10|

---

JP2015500806A|2015-01-08|

---

MX2014006361A|2015-03-05|

---

MX361893B|2018-12-18|

---

PE20141482A1|2014-11-08|

---

CN104159604A|2014-11-19|

---

HK1200018A1|2015-07-31|

---

SI2785374T1|2019-04-30|

---

HUE047909T2|2020-05-28|

---

RU2620936C2|2017-05-30|

---

EP3578199A1|2019-12-11|

---

SI3251691T1|2020-02-28|

---

DK2785374T3|2019-04-08|

---

WO2013082317A2|2013-06-06|

---

LT2785374T|2019-04-25|

---

PT3251691T|2020-01-28|

---

HRP20192215T1|2020-02-21|

---

BR112014013276A2|2018-05-15|

---

EP3263130A1|2018-01-03|

---

EP3251691A1|2017-12-06|

---

HK1197175A1|2015-01-09|

---

IN2014CN04833A|2015-09-18|

---

CA2857025C|2021-08-03|

---

PH12014501174A1|2014-09-08|

---

RU2014126375A|2016-01-27|

---

CA2857025A1|2013-06-06|

---

JP6149301B2|2017-06-21|

---

KR102013135B1|2019-08-22|

---

HRP20190525T1|2019-05-03|

---

CN104159604B|2016-08-24|

---

EP3251691B1|2019-11-20|

---

PT2785374T|2019-05-09|

---

ES2785045T3|2020-10-05|

---

EP2785373B1|2019-11-20|

---

LT2785373T|2020-02-10|

---

CN104159605A|2014-11-19|

---

ME03433B|2020-01-20|

---

CO7061033A2|2014-09-19|

---

PL2785374T3|2019-07-31|

---

EP2785373A1|2014-10-08|

---

PL2785373T3|2020-06-01|

---

WO2013082317A8|2014-07-10|

---

EP2785374A2|2014-10-08|

---

PT2785373T|2020-01-27|

---

WO2013082317A3|2013-08-15|

---

HK1247832A1|2018-10-05|

---

HUE047724T2|2020-05-28|

---

WO2013082327A8|2014-07-03|

---

EP3572092A1|2019-11-27|

---

MX2014006360A|2015-03-05|

---

DK3251691T3|2020-02-10|

---

RS59893B1|2020-03-31|

---

AR089039A1|2014-07-23|

---

CN105920598A|2016-09-07|

---

PH12014501174B1|2014-09-08|

---

PL3251691T3|2020-06-01|

---

WO2013082327A1|2013-06-06|

---

LT3251691T|2020-02-10|

---

ZA201403804B|2015-04-29|

---

ES2719409T3|2019-07-10|

---

RS59892B1|2020-03-31|

---

EP2785374B1|2019-01-09|

---

CN104159605B|2019-04-19|

---

RS58610B1|2019-05-31|

---

PH12015502790A1|2017-07-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4722848A|1982-12-08|1988-02-02|Health Research, Incorporated|Method for immunizing animals with synthetically modified vaccinia virus|

---

US5174993A|1981-12-24|1992-12-29|Health Research Inc.|Recombinant avipox virus and immunological use thereof|

---

US4769330A|1981-12-24|1988-09-06|Health Research, Incorporated|Modified vaccinia virus and methods for making and using the same|

---

US4603112A|1981-12-24|1986-07-29|Health Research, Incorporated|Modified vaccinia virus|

---

EP0138854B1|1983-03-08|1992-11-04|Chiron Mimotopes Pty. Ltd.|Antigenically active amino acid sequences|

---

US5853733A|1993-02-26|1998-12-29|Syntro Corporation|Recombinant herpesvirus of turkeys and uses thereof|

---

US6183753B1|1994-08-09|2001-02-06|Schering-Plough Veterinary Corp.|Recombinant chimeric virus and uses thereof|

---

CA2626498C|1994-08-09|2011-04-12|Schering-Plough Limited|Recombinant chimeric virus|

---

EP0256092B1|1986-01-27|1998-04-08|Syntro Corporation|Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same|

---

JP2779447B2|1988-03-20|1998-07-23|財団法人阪大微生物病研究会|Method for producing recombinant gene using attenuated Marek's disease virus vector and recombinant of the virus|

---

EP0431668B1|1989-12-04|1995-02-15|Akzo Nobel N.V.|Recombinant herpesvirus of turkeys and live vector vaccines derived thereof|

---

KR100242671B1|1991-03-07|2000-03-02|고돈 에릭|Genetically engineered vaccine strain|

---

BE1004877A3|1991-05-27|1993-02-16|Solvay|RECOMBINANT AVIPOX VIRUS, CULTURE OF CELLS INFECTED WITH THIS VIRUS AND POULTRY VACCINES DERIVED FROM THIS VIRUS.|

---

FR2719056B1|1994-04-20|1996-09-06|Rhone Merieux|Herpesvirus transformed to express gD in vitro.|

---

RU2059414C1|1994-12-09|1996-05-10|Государственная Курская биофабрика - Фирма "БИОК"|Multipartial vaccine for mareck disease prophylaxis and a method of its preparing|

---

FR2728795B1|1994-12-30|1997-03-21|Rhone Merieux|AVIAN RECOMBINANT LIVING VACCINE USING AVIAN HERPES VIRUS AS A VECTOR|

---

JPH104956A|1996-06-21|1998-01-13|Univ Michigan State|Improvement in maintainable cell strain in order to produce vaccine for marek's disease|

---

FR2751225B1|1996-07-19|1998-11-27|Rhone Merieux|AVIAN POLYNUCLEOTIDE VACCINE FORMULA|

---

JP4111403B2|1996-10-11|2008-07-02|ザリージェンツオブザユニバーシティーオブカリフォルニア|Immunostimulatory polynucleotide / immunomodulatory molecule complex|

---

US5980912A|1997-03-25|1999-11-09|Zonagen, Inc.|Chitosan induced immunopotentiation|

---

EP1026246B1|1997-10-03|2006-11-29|Zeon Corporation|Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same|

---

EP0974660A1|1998-06-19|2000-01-26|Stichting Instituut voor Dierhouderij en Diergezondheid |Newcastle disease virus infectious clones, vaccines and diagnostic assays|

---

US6299882B1|1999-04-09|2001-10-09|Schering Corporation|UL54.5 of Marek's disease virus |

---

KR100354972B1|2000-04-11|2002-10-05|대한민국|Recombinant Marek's disease virus type 2 expressing the S1 glycoprotein of infectious bronchitis virus and a method for constructing thereof|

---

US6764684B2|2001-09-28|2004-07-20|Zeon Corporation|Avian herpesvirus-based recombinant infectious bursal disease vaccine|

---

US6866852B2|2002-01-31|2005-03-15|Zeon Corporation|Recombinant herpesvirus of turkeys and use thereof|

---

KR100801180B1|2006-09-26|2008-02-05|주식회사 고려비엔피|Attenuated recombinant newcastle disease virus and vaccine containing the same|

---

CN102405058B|2009-04-15|2015-11-25|法国诗华大药厂|For restructuring avian herpetoviruses carrier and the vaccine of immunity inoculation aquatic bird species|

---

IN2014CN04833A|2011-11-30|2015-09-18|Merial Ltd|JP6134324B2|2011-10-21|2017-05-24|インターベット インターナショナル ベー． フェー．|Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and Newcastle disease virus antigens|

---

IN2014CN04833A|2011-11-30|2015-09-18|Merial Ltd|

---

EP2644702A1|2012-03-30|2013-10-02|Ceva Sante Animale|Multivalent recombinant avian herpes virus and vaccine for immunizing avian species|

---

AR097029A1|2013-07-26|2016-02-17|Intervet Int Bv|ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE|

---

EP2845904A1|2013-09-06|2015-03-11|Ceva Sante Animale|Recombinant Marek's disease viruses and uses thereof|

---

AR103245A1|2014-12-24|2017-04-26|Intervet Int Bv|HVT-BASED VECTOR VACCINEAGAINST ND- IMPROVED IBD |

---

US10537628B2|2015-08-10|2020-01-21|The Texas A&M University System|Recombinant turkey herpesvirus vaccines and uses thereof|

---

KR20190073460A|2016-10-21|2019-06-26|뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드|Recombinant vectors expressing antigens of avian influenza virus and uses thereof|

---

BR112019012280A2|2016-12-14|2019-11-26|Boehringer Ingelheim Animal Health Usa Inc|recombinant hvt vectors expressing multiple avian pathogen antigens and vaccines comprising the same|

---

CN106701693A|2017-01-19|2017-05-24|北京邦卓生物科技有限公司|Construction and application of recombinant herpesvirus of turkey for expressing GB gene of serum I type Marek's disease virus|

---

CN106929483B|2017-01-19|2020-09-25|北京邦卓生物科技有限公司|Construction and application of recombinant turkey herpesvirus expressing newcastle disease virus F gene|

---

EP3391903B1|2017-04-21|2022-02-23|The Pirbright Institute|Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens|

---

CN107099513B|2017-06-22|2020-07-14|北京邦卓生物科技有限公司|Construction and application of HVT co-expressing NDV HN and IBDV VP2 genes|

---

CN107254450A|2017-07-20|2017-10-17|扬州大学|The chimeric Newcastle Disease Virus Vaccine carrier Candidate Strain and construction method for overcoming newcastle disease maternal antibody to influence|

---

CN107603958A|2017-09-29|2018-01-19|天津农学院|The construction method and recombined adhenovirus of the genes of amalgamation and expression TM 1 and gD gene recombinant adenovirus and application|

---

US11229698B2|2017-10-12|2022-01-25|Intervet Inc.|Recombinant non-pathogenic Marek's Disease virus constructs encoding multiple heterologous antigens|

---

EP3727431A1|2017-12-20|2020-10-28|Intervet International B.V.|Improved diluent for cell-associated alphaherpesvirus vaccine|

---

CN108543067A|2017-12-25|2018-09-18|中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心）|Co-express the recombinant herpesvirus of turkeys vaccine strain of H5 subtype avian influenza HA albumen and infectious bursa of Fabricius VP2 albumen|

---

CN109468315B|2018-12-07|2021-09-07|袁隆平农业高科技股份有限公司|Rice flooding-resistant gene Sub1 codominant molecular marker and application thereof|

---

EP3897709A1|2018-12-21|2021-10-27|Ceva Santé Animale|Recombinant avian herpes viruses containing multiple foreign genes|

---

US20210196811A1|2019-09-11|2021-07-01|Zoetis Services Llc|Recombinant Herpesvirus of Turkey Vectors Expressing Antigens of Avian Pathogens and Uses Thereof|

---

US20210324016A1|2020-04-15|2021-10-21|The United States Of America, As Represented By The Secretary Of Agriculture|Recombinant vaccine against marek's disease and newcastle disease|

---

WO2021257706A1|2020-06-17|2021-12-23|Boehringer Ingelheim Animal Health USA Inc.|Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof|

法律状态:
2018-07-03| B25C| Requirement related to requested transfer of rights|Owner name: MERIAL LIMITED (US) |

---

2018-08-28| B25A| Requested transfer of rights approved|Owner name: MERIAL, INC. (US) |

---

2019-08-13| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-09-01| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]|

---

2021-05-18| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-07-27| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161564877P| true| 2011-11-30|2011-11-30|

---

US61/564,877|2011-11-30|

---

US201261694957P| true| 2012-08-30|2012-08-30|

---

US61/694,957|2012-08-30|

---

PCT/US2012/067135|WO2013082327A1|2011-11-30|2012-11-29|Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof|

---